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1.1 MOLECULAR MODELING IN MEDICINAL CHEMISTRY 
One of the main goals of medicinal chemistry is the rational design of new 
compounds able to produce a biological effect. This objective is now increasingly 
achieved through the use of molecular modeling methodologies which allow to study 
in silico the atomic details of the interaction between ligands and biological targets 
and to simulate their dynamic behaviour using the equations of classical and 
quantum physics. This information can be successfully applied to the evaluation of 
new molecules in the design stage, with the aim of directing the synthesis only on the 
most promising compounds. Moreover, molecular modeling methods can be applied 
to the investigation of biophysical phenomena, such as the conformational flexibility 
of macromolecular targets, at atomistic level.  
One of the basic principles of medicinal chemistry is that biological activity of a 
compound is dependent on the three-dimensional placement of specific functional 
groups which interacts with complementary regions in macromolecular targets 
(proteins or DNA molecules). The application and development of the molecular 
modeling methodologies in the pharmaceutical research has been mainly promoted 
by the increasing availability of the three-dimensional structures of biological targets 
solved at the atomic level through X-ray crystallography or NMR spectroscopy, as 
well as by the improvement in computer hardware and software. 
The computational approaches employed in the drug discovery can be divided into 
two main classes: 
? Structure Based Drug Design (SBDD), in which the starting point is the 
knowledge of the three-dimensional (3D) structures of biological targets, 
solved experimentally or built by homology modeling; 
? Ligand Based Drug Design (LBDD), which uses information derived from 
the analysis of a series of molecules interacting with the same 
pharmacological profile to the same target to obtain a picture of those target 
features necessary for ligand interaction. 
In this thesis work we deal with methodologies related to a SBDD approach, 
exploiting the availability of experimental three-dimensional structures for the targets 
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or complementing gaps in the available experimental data through the use of 
homology modeling. We have employed classical methods like molecular docking
and Molecular Dynamics simulations (MD) and more recent methodologies which 
enable a more efficient exploration of the conformational space of complex 
macromolecules (sampling methods) and an accurate evaluation of the free energy 
(?Gbinding) related to the binding process between ligands and macromolecules (free
energy methods).
Here, we will describe two applications of the aforementioned methodologies taken 
as an example. MD simulations and advanced sampling methods have been applied 
to the investigation of the tyrosine kinase domain belonging to the membrane 
receptor VEGFR2, while molecular docking, MD simulations and the MM-PBSA 
method for the evaluation of the binding free energy have been applied to the 
investigation of the behaviour of a series of acridine-based polyamine ligands in the 
binding of double helix and G-quadruplex DNA structures. In addition to these, in 
the appendix section of this thesis is reported a molecular docking study on the 
binding modes of newly synthesized iminosugars towards the enzyme glucoamylase 
(GA) from Aspergillus awamori.
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1.2 RECEPTOR TYROSINE KINASES 
1.2.1 Receptor Tyrosine Kinases: general features 
Human Receptor Tyrosine Kinases (RTKs) represent a class of transmembrane 
glycoproteins involved in controlling the transduction of extracellular signals to the 
cytoplasm through the selective phosphorylation of tyrosine residues on proteins, 
often other kinases, or even themselves (autophosphorylation). [1] These receptors 
bind ATP-Mg2+ and catalyze the transfer of the ?-phosphoryl group from ATP to 
hydroxyls of tyrosine side chains in a protein substrate: 
MgATP1- + protein-OH ?  protein-OPO32- + MgADP + H+
Several important targets in medicinal chemistry belong to this family of receptors 
including, among the others, the insulin receptor (InsR), involved in the stimulation 
of carbohydrate utilization, and the Vascular Endothelial Growth Factor Receptors 
(VEGFRs), involved in controlling physiological processes like vasculogenesis (the 
formation of new blood vessels) and angiogenesis (the growth of pre-existing blood 
vessels). The activation of these receptors is induced by the binding to their 
extracellular domain of some polypeptides acting as signal molecules, like the 
hormone insulin and the Vascular Endothelial Growth Factors (VEGFs), which 
include VEGF-A, VEGF-B, VEGF-C, VEGF-D and Placental Growth Factor 
(PIGF). [2] Over the past several years, the knowledge of the functionality of these 
receptors and of the structural bases for their regulation has been provided by the 
increasing availability of high-resolution crystal structures solved both in active and 
inactive states together with biochemical, genetic and modeling studies. [3] 
However, some fundamental aspects regarding these key events are not well 
understood and one of the most attractive challenges of molecular modeling is now 
the application of computational techniques in order to achieve a deeper knowledge 
of these targets and of their conformational flexibility starting from the available 
structural data. 
Despite the great number of common features, some variability among RTKs can be 
observed in their overall architecture. Most of these receptors, like VEGFRs, are 
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monomer in their inactive forms with a single polypeptide chain passing through the 
membrane and undergo oligomerization after ligand binding. Other kinases consist of 
more than one polypeptide chain; for instance the insulin receptor is formed even in 
its inactive state by four subunits (?2?2), two of them (? units) spanning the cellular 
membrane. [2]  
1.2.2 Vascular Endothelial Growth Factor Receptors 
In this thesis work the attention was focused on the investigation of the VEGFRs. 
These receptors have recently emerged as attractive targets in pharmaceutical and 
clinical research because the processes of angiogenesis and vasculogenesis in which 
they are involved, have been recognized as key steps in several diseases like tumor 
growth and spread, diabetic retinopathy and arthritis [4-7]. At the moment three 
different human VEGFRs are known (VEGFR1, VEGFR2 and VEGFR3), located on 
the surface of vascular endothelial cells and formed by a single polypeptide chain 
spanning the cellular membrane. [8] 
Human VEGFR2 (also known as FLK-1, fetal liver kinase-1) is a protein constituted 
by 1356 amino acids and seems to be the major transducer for signals induced by 
VEGFs, both in physiological and pathological situations, and can be chosen as 
representative member of this class of proteins. [9] 
Structurally it can be divided into different regions (Fig.1.2.1): 
? an extracellular domain containing seven immunoglobulin (Ig)-like domains 
and involved in the binding of growth factors (VEGFs); 
? a single short transmembrane segment; 
? a juxtamembrane region; 
? a cytoplasmic domain possessing tyrosine kinase catalytic activity, referred to 
as KDR domain, which is split into two portions by the so called kinase insert 
domain (KID). The catalytic domain is the most conserved region among 
RTKs;
?  a carboxyl terminal domain. 
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Fig.1.2.1 A simplified representation of the global architecture of the 
human VEGFR2 in the dimeric form. 
In detail (Fig.1.2.1), growth factors bind, according to a not yet fully explained 
mechanism, the second and third extracellular immunoglobulin domains belonging to 
two monomeric receptors. This step leads to protein dimerization, activation of the 
intracellular kinase activity and trans-autophosphorylation of tyrosine residues 
located in the cytoplasmic subunits. [10] This trans-autophosphorylation requires a 
dimer receptor in which a monomer, with the structural features described above, 
assumes the function of substrate and the other serves as the enzyme. 
Phosphorylation of tyrosine residues located in a particular flexible segment in the 
center of the kinase domain, referred to as the “activation loop” (A-loop), promotes 
the enhancement of the kinase activity, while phosphorylated residues in other 
cytoplasmic regions of the target become in turn binding sites for other proteins 
involved in the subsequent signal propagation, such as the SH2- (Src Homology 2) 
and the PTB- (Phospho-Tyrosine Binding) domain containing proteins. [11] 
A deeper knowledge of this mechanism of signal transduction will be possible when 
the three-dimensional structure of the whole human receptor VEGFR2 is available. 
At the moment, in fact, only some regions have been solved by X-ray diffraction for 
this receptor and their three-dimensional structures are collected in the Protein Data 
Bank (PDB) [12]:
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? the three-dimensional structures of the second and third Ig-like extracellular 
domains in complex with VEGF-C (pdb codes 2X1W and 2X1X [13]); 
? the structure of the seventh Ig-like extracellular domain (pdb code 3KVQ 
[14]).
Both these structures have been reported when our studies on VEGFR2 were 
already begun. 
? the crystal structure of the cytoplasmic KDR domain, the only available at the 
beginning of this thesis work.  
1.2.3 The structure of the KDR domain 
The first crystal structure of the KDR domain was reported in 1999 by McTigue et 
al. [15]; at present 22 X-ray three-dimensional structures of this kinase domain are 
available in the PDB, both in their apo form and in complex with inhibitors 
(Table.1.2.1). It is worth noting that none of the crystal structures is completely 
solved. All the structures lack, indeed, a portion of the kinase insert domain (KID), 
whose removal seems to be necessary for the crystallization of the protein. [15] 
Moreover, only one structure (pdb code 2OH4 [16]) has the coordinates for the so-
called A-loop, although with high temperature factors (B-factors) associated with the 
corresponding atoms. This activation segment in the other structures is either 
partially solved or not solved at all. For these reason the structure 2OH4 has been 
chosen as reference structure for the study on this macromolecular target and taken 
as representative for the description of KDR. Its coordinates correspond to the 
residues comprised between His814 and Asp1169 of the VEGFR2 primary sequence 
(Fig.1.2.2); the non solved region, belonging to the KID, corresponds to the residues 
between Tyr936 and Tyr994.
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Table.1.2.1 Crystal structures of the KDR domain available, at the moment, in the PDB. 
PDB CODE Descriptor 
Resolution
(Å)
Source Reference 
1VR2 VEGFR2 (KDR) kinase domain 2.40 Homo sapiens 15
2OH4 
VEGFR2 kinase domain in complex a 
benzimidazole-urea inhibitor 2.05 
Homo 
sapiens 16
3EFL 
VEGFR2 kinase domain in complex with 
motesanib 2.20 
Homo 
sapiens 17
3EWH
VEGFR2 kinase domain in complex with a 
pyridyl-pyrimidine benzimidazole inhibitor 1.60 
Homo 
sapiens 18
3C7Q 
VEGFR2 kinase domain in complex with 
BIBF1120 2.10 
Homo 
sapiens 19
3CJF 
VEGFR2 in complex with a 3,4,5-trimethoxy 
aniline containing pyrimidine 2.15 
Homo 
sapiens 20
3CJG 
VEGFR2 in complex with a 3,4,5-trimethoxy 
aniline containing pyrimidine 2.25 
Homo 
sapiens 20
3DTW
VEGFR2 kinase domain in complex with a 
benzisoxazole inhibitor 2.90 
Homo 
sapiens 21
3CP9 
VEGFR2 kinase domain in complex with a 
pyridone inhibitor 2.50 
Homo 
sapiens 22
3CPB 
VEGFR2 kinase domain in complex with a 
bisamide inhibitor 2.70 
Homo 
sapiens 22
3CPC 
VEGFR2 kinase domain in complex with a 
pyridone inhibitor 2.40 
Homo 
sapiens 22
2RL5
VEGFR2 kinase domain in complex with a 2,3-
dihydro-1,4-benzoxazine inhibitor 2.65 
Homo 
sapiens 23
3BE2
VEGFR2 kinase domain in complex with a 
benzamide inhibitor 1.75 
Homo 
sapiens 24
3B8Q 
VEGFR2 kinase domain in complex with a 
naphthamide inhibitor 2.75 
Homo 
sapiens 24
3B8R
VEGFR2 kinase domain in complex with a 
naphthamide inhibitor 2.70 
Homo 
sapiens 25
2QU5 
VEGFR2 kinase domain in complex with a 
benzimidazole inhibitor 2.95 
Homo 
sapiens 26
2QU6 
VEGFR2 kinase domain in complex with a 
benzoxazole inhibitor 2.10 
Homo 
sapiens 26
2P2H 
VEGFR2 kinase domain in complex with a 
pyridinyl-triazine inhibitor 1.95 
Homo 
sapiens 27
2P2I 
VEGFR2 kinase domain in complex with a 
nicotinamide inhibitor 2.40 
Homo 
sapiens 27
1YWN
VEGFR2 kinase domain in complex with a novel 
4-amino-furo[2,3-d]pyrimidine 1.71 
Homo 
sapiens 28
1Y6A
VEGFR2 kinase domain in complex with a 2-
anilino-5-aryl-oxazole inhibitor 2.10 
Homo 
sapiens 29
1Y6B
VEGFR2 kinase domain in complex with a 2-
anilino-5-aryl-oxazole inhibitor 2.10 
Homo 
sapiens 29
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Fig.1.2.2 A schematic representation of the crystal structure 2OH4. It is worth noting that the 
numbering used in the structure 2OH4 is shifted by two residues compared to that used in the primary 
sequence of the receptor VEGFR2 (UniProtKB sequence: P35968, VEGFR2_HUMAN). The residues 
814 and 1169 of 2OH4 are actually the 816 and 1171 residues of the VEGFR2 primary sequence.  
The structural analysis of the crystallographic data reveals, in the KDR domain, the 
same overall architecture which is found in most of the tyrosine kinase domains. In 
detail, the KDR domain (Fig.1.2.3) has the characteristic bilobed structure highly 
conserved among eukaryotic Ser/Thr and Tyr kinases with a smaller N-terminal lobe 
(residues 814-915; light blue in the Fig.1.2.3) consisting mainly of antiparallel ?-
sheets, apart from an important ?-helix (?C-helix, corresponding to residues 874-
890; blue in the Fig.1.2.3), and a larger C-terminal lobe comprising the residues 922-
1169 and mainly formed by ?-helices (orange in the Fig.1.2.3). The binding site for 
ATP-Mg2+ is located in the cleft between the N- and C-terminal lobes, joined 
together by a conserved segment, referred to as the “hinge region” FCKFGN
(residues 916-921, using the one-letter code for amino acids; pink in the Fig.1.2.3). 
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Fig.1.2.3 A schematic representation of the global architecture 
found in the KDR domain (crystal structure 2OH4 [16]).  
Some regions of the KDR domain contain residues highly conserved in all protein 
kinases and involved in essential structural and dynamic roles.  
In detail there are: 
N-terminal lobe 
? the glycine rich loop GRGAFG (residues 839-844, yellow in Fig.1.2.3) which 
defines the top of the ATP binding site; 
? the residue Lys866, located in the so-called strand ?3 and 
? the residue Glu883 located in the ?C-helix.
Residues Lys866 and Glu883 are involved in the complex mechanism of the A-loop 
transition from the inactive (closed) to the active (open or extended) form in kinases. 
This transition is also accompanied by the movements of the ?-sheets in the N-
terminal lobe as a rigid body. Moreover, the ?C-helix undergoes to a rotation, upon 
the A-loop movement, which places the conserved Glu883 residue in proximity to 
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the conserved Lys866. The rotation of the N-terminal lobe towards the C-terminal 
lobe brings Lys866 and Glu883 into position for the proper ATP-Mg2+ binding. 
C-terminal lobe 
? the catalytic loop HRDLAARN (residues 1024-1031, green in Fig.1.2.3); 
? the activation loop (residues 1044-1073, also called A-loop or T-loop, red in 
Fig.1.2.3), a centrally located regulatory element in protein kinases 
In the catalytic loop (HRDLAARN) the first three amino acids (HRD motif, 
His1024, Arg1025, Asp1026) are the most conserved among protein tyrosine 
kinases, with the Asp1026 which acts as catalytic base in the phosphotransfer 
reaction (Fig.1.2.4).  
The A-loop, completely solved only in the crystal structure 2OH4, begins with the 
characteristic DFG motif (Asp1044-Phe1045-Gly1046), highly conserved among 
protein kinases, and ends with the APE motif (Ala1071-Pro1072-Glu1073).  
The A-loop is formed by: 
(1) the magnesium binding loop, DFGLA (residues 1044-1048), in which the first 
residue, Asp1044, binds the Mg2+ ion during the phosphotranfer reaction. The Mg2+
in turn coordinates the phosphate group ? and ? in ATP (Fig.1.2.4); 
(2) the so-called strand ?9;
(3) the activation segment, YpKDPDYp (residues 1052-1057), which contains two 
tyrosine residues undergoing phosphorylation (Tyr(P)1052-Tyr(P)1057).  
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Fig.1.2.4 A schematic representation of the mechanism proposed for 
the reaction catalyzed by an active tyrosine kinase.  (Adapted from 
reference [30]) 
The A-loop has been recognized as one of the most flexible portions of the kinase 
domain and can exist in different conformations, in a dynamic equilibrium controlled 
by the phosphorylation; this mobility is consistent with the high disorder observed in 
the crystal structure. Two limit conformations are supposed for this loop, 
corresponding to the inactivated and catalytically active state of the kinase. The 
double phosphorylation of the tyrosine residues should stabilize the A-loop in its 
active conformation. [31] In this active (open or extended) conformation, the 
Asp1044 residue of the DFG motif at the N-terminal end of the A-loop is positioned 
so as to interact properly with the Mg2+ which coordinates two phosphate groups of 
the ATP (Fig.1.2.4). The structure 2OH4 is a bit unusual in that, although double 
phosphorylated, its A-loop is in an inactive conformation, where the DFG motif 
adopts a so-called “out” conformation, with the phenyl ring of the side chain of the 
residue Phe1045 pointing towards the ATP binding site, in a position that actually 
does not allow the coordination of the magnesium ion by the residue Asp1044. [8]  
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In the KDR domain is also present, in the C-terminal lobe, the so-called kinase insert 
domain (KID), which split the kinase domain in two regions. The KID domain 
corresponds to the residues 931-998 and is partially deleted in all the crystallized 
proteins available in the PDB, including 2OH4 (residues 936-994; purple in the 
Fig.1.2.3). It has been demonstrated that most of the KID domain, far away from the 
catalytic site and from the A-loop, is not necessary for the kinase activity. KID is, 
however, important as binding site for other proteins, after phosphorylation of two of 
its tyrosine residues, and as a linker which connects two ?-helices in the C-terminal 
lobe and maintains the overall architecture of the KDR domain. [15] 
1.2.4 Conformational flexibility of the kinase domain 
Structural and computational studies performed on kinases solved in active and 
inactive states have made possible to point out two main conformational motions 
associated with the transition from the inactive to the active state: a change in the 
orientation of both the ?C-helix in the N-terminal lobe and the A-loop in the C-
terminal lobe. [32-34] These movements are in turn followed by changes in other 
structural elements. The dynamic of the A-loop, for example, affects the 
conformation of the characteristic DFG motif; the conformational switch of this 
flexible motif is referred to as “DFG flip”. In the active conformation, the Asp1044 
(using the numbering of 2OH4) residue of the DFG motif points towards the ATP 
binding cleft and the phenylalanine is buried in a hydrophobic pocket adjacent to the 
ATP site; this orientation is referred to as DFG-in. In the other limit orientation, the 
so-called DFG-out conformation, the DFG aspartate and phenylalanine side chains 
swap positions and point in opposite directions compare to the DFG-in orientation.
In the DFG-out conformation, the phenylalanine side chain points towards the ATP 
binding site and thus creates a hydrophobic pocket (named allosteric hydrophobic 
pocket), adjacent to the ATP-binding site. On the other side, the conformational 
change in the ?C-helix affects the mutual orientation of two highly conserved 
residues, namely Glu883 and Lys866. These two residues strongly interact via a salt 
bridge, and Lys866 contributes to the proper orientation of the ? and ? phosphate 
ATP groups during the catalysis (Fig.1.2.4). The ?C-helix movement also causes a 
slight shift of the glycine-rich loop.
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Once the target is in its active state, another type of conformational change occurs in 
the kinase domain: the N- and C-terminal lobes move relative to each other to open 
and close the binding cleft. 
All these conformational motions occur during the catalytic cycle, which involves in 
a first step the binding of ATP and protein substrate to the open conformation of the 
target. Once the complex is formed, the catalyzed reaction occurs in the closed 
conformation, and ADP and the phosphorylated substrate are released during the 
subsequent evolution to the open state that completes this cycle. [34] 
In general, it has emerged that, while the inactive states of the kinase domains show a 
great structural variability among RTKs, the active state is essentially invariant from 
a structural perspective. [35, 36] Recently, it has also been shown that all active 
conformations are strongly stabilized by a “hydrophobic spine”, which traverses both 
the N- and C-terminal lobes. This spine is instead disordered in the inactive forms of 
kinases and this can explain the higher variability observed for these conformations. 
[32, 33]
The tyrosine kinase domain of the human insulin receptor can be chosen as a suitable 
example to show the conformational changes which occur during the activation 
process. Its crystal structure, in fact, has been solved in two different conformations, 
corresponding to the inactive (closed) and active (open) form (pdb codes 1IRK [37] 
and 1IR3 [38]) (Fig.1.2.5). In the unphosphorylated structure (1IRK) the A-loop is 
oriented in order to prevent the binding of ATP-Mg2+ and of the protein substrate. In 
the active and phosphorylated conformation (1IR3), we observe a considerable 
change in the orientation of the A-loop, which enable the binding of ATP-Mg2+ and 
an efficient phosphorylation of the protein substrate. A significant change can also be 
observed in the orientation of the highly conserved DFG motif, which assumes 
respectively a DFG-out and a DFG-in conformation, and in the orientation of the 
?C-helix in the N-terminal lobe.  
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Fig.1.2.5 Ribbon representation of: a) the inactive conformation (crystal 
structure 1IRK) and b) the active conformation (crystal structure 1IR3) of 
the kinase domain of the human insulin receptor. The A-loop is coloured in 
red: a) closed conformation for the A-loop and b) open conformation for 
the A-loop. The DFG motif is highlighted in yellow: a) DFG-out
orientation and b) DFG-in orientation.  
To the best of our knowledge, a comprehensive (structural or computational) study 
which provides a detailed description of the activation mechanism at the atomistic 
level has not been previously reported on the KDR domain. 
1.2.5 Inhibitors of Receptor Tyrosine Kinases 
Receptor tyrosine kinases represent an attractive target in oncology drug discovery. 
In this context, the detailed knowledge of the conformational flexibility of their 
kinase domains is of remarkable value since the inhibition of RTKs has been mainly 
achieved through highly potent small organic compounds binding the ATP pocket. In 
particular, the conformational variability of the DFG motif has been employed in the 
design of protein kinase inhibitors. 
These compounds can act or by mimicking the ATP binding mode to the kinase 
domain in its active and DFG-in conformation (ATP-competitive inhibitors) or by 
locking kinases in their inactive and DFG-out state (non-ATP competitive 
inhibitors). [39]
Compounds targeting the ATP binding site in the active and DFG-in conformation 
are generally referred to as type-I inhibitors (Fig.1.2.6). A common feature of the 
a) b) 
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type-I inhibitors is their ability to bind to the ATP site mimicking the adenine ring in 
its interactions with the “hinge” residues of the protein. The non-ATP competitive 
inhibitors, which bind the inactive and DFG-out conformations, are defined as type-
II inhibitors (Fig.1.2.6). In the DFG-out form, the aromatic ring of the phenylalanine 
residue (Phe1045 in the crystal structure 2OH4 [16]) points towards the ATP pocket 
and creates, near the ATP-binding site, an allosteric hydrophobic binding pocket 
suitable for occupation by type-II kinase inhibitors. Type-II inhibitors bind 
simultaneously to the ATP binding site and to the allosteric hydrophobic pocket. 
Recently compounds which bind exclusively within the allosteric pocket have also 
been identified and are referred to as type-III inhibitors. [39-41]
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Fig.1.2.6 Examples of type-I and type-II kinase inhibitors approved by 
the FDA for cancer treatment 
Because of the highly conserved architecture of the kinase domains among RTKs, 
the discovery of selective inhibitors, which bind only to one kinase and not to others, 
is a fundamental challenge in oncology drug-discovery. The deep knowledge of the 
conformation of the A-loop, ?C-helix and other related structural elements in the 
active and inactive states, as well as the knowledge at atomic level of the path 
connecting these two limit conformations and particularly of the DFG flip, is thus 
crucial for providing a platform for the rational design of highly selective kinase 
inhibitors.
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1.2.6 Motivation and Aims of the work
VEGFR2 belongs to the tyrosine kinase receptor family. It is involved both in 
physiological and pathological angiogenesis and vasculogenesis. It has been 
recognized as an attractive target in anticancer therapies. In this thesis work we have 
investigated the structural and dynamic features of its kinase domain, the KDR 
domain. In a first step, through the application of molecular modeling strategies, we 
have tried to characterize the active and inactive conformations of this target, 
completing the gaps in the available crystallographic data. In a second step, we have 
investigated the KDR domain in order to obtain a detailed description at atomic level 
of the transition from the inactive to the active conformation. In this stage, molecular 
dynamics simulations and advanced sampling methods have been applied to model 
the KDR flexibility and to sample intermediate conformations which can be used in 
the rational design of selective inhibitors for this target. 
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1.3 DNA: DOUBLE HELIX AND G-QUADRUPLEX STRUCTURES 
1.3.1 DNA double-stranded
The activity of many antimalarial, antibacterial and anticancer agents is based on 
their interaction with helical double-stranded DNA (dsDNA). [42-44] As a 
consequence, much effort has been devoted over the past few decades to the design 
and synthesis of new molecules that can reversibly bind and/or react with dsDNA. 
The double helical structure model for the DNA was proposed for the first time by 
Watson and Crick in 1953. [45] In this canonical DNA structure, always referred to 
as the B-DNA structure, two strands of DNA are coiled around a common axis and 
linked together by specific hydrogen-bonds involving a purine and a pyrimidine base 
according to the scheme Adenine (A) – Thymine (T) and Guanine (G) – Cytosine 
(C), known as Watson and Crick base pairing. This double helix is right handed with 
antiparallel backbone chains and ten nucleotides per turn. The bases are located on 
the inner part of the helix and the phosphate groups are on the outside. On average, 
the distance between adjacent base pairs is 3.4Å. The two strands make two grooves 
of different widths, referred to as the major groove and the minor groove (Fig.1.3.1).  
Fig.1.3.1 Features of the B-DNA Watson and Crick model. (Adapted from reference [46]) 
Several studies on DNA sequences, subsequent the assumption of Watson and Crick 
about the double-stranded structure, have revealed a high flexibility and 
polymorphism of DNA which is able to adopt different three-dimensional folded 
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structures. [47] Non-canonical DNA structures can arise from either a different base 
pairing A-T and C-G compared to that of Watson and Crick, such as the Hoogsteen 
and reverse Hoogsteen hydrogen bonding schemes, or a purine-purine base pairing, 
such as the G-G base pairing (Fig.1.3.2). [48-50] 
Fig.1.3.2 Hoogsteen and reverse-Hoogsteen A-T base pair hydrogen 
bonding schemes, compared with A-T Watson and Crick hydrogen 
bonding scheme in B-DNA. Hoogsteen hydrogen bonding scheme for G-G 
(Adapted from reference [46]) 
Among these non-standard structures, recently a great deal of attention has been 
devoted to clarifying the structural features of G-quadruplexes observed in the 
telomeric DNA. [51-55] 
1.3.2 G-quadruplex DNA structures
Guanine quadruplexes (G-quadruplexes) are unconventional DNA secondary 
structures that consist of at least two stacked building blocks, referred to as G-
quartets or G-tetrads, formed in turn by four guanines associated together into a 
cyclic and planar arrangement through a network of eight Hoogsteen hydrogen 
bonds. [56] These coplanar cyclic arrays are connected and stabilized by monovalent 
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cation such as K+ or Na+ located in the negatively charged hole between stacked G-
tetrads. The different G-quartet plans are at an average distance of 3.4Å (Fig.1.3.3). 
Fig.1.3.3 A schematic drawing of an intra-molecular G-quadruplex folding 
induced by a metal ion. A G-tetrad plane is composed of four guanines 
connected by eight Hoogsteen hydrogen bonds. 
A higher polymorphism, compared to double stranded DNA, can be found in G-
quadruplex structures. First, G-quadruplexes can be formed either from a single tract 
of G-rich sequence of DNA (intramolecular G-quadruplexes), or from the association 
of two or four separate strands (dimeric and tetrameric G-quadruplexes). Moreover, 
the four-stranded phosphodiester chains of all G-quadruplexes can be found in 
different relative arrangements: all parallel (Fig.1.3.4 a)), three-parallel and one anti-
parallel (Fig.1.3.4 b)), adjacent parallel (Fig.1.3.4 c)) and alternating parallel 
(Fig.1.3.4 d)).
Fig.1.3.4 Strand polarity in G-quadruplexes. (Adapted from reference [46]) 
Another contribution to the resultant diversity in G-quadruplex topologies is given by 
a high variability in the sequences connecting the different G-quartets in dimeric and 
monomeric G-quadruplexes. These loops (TTA loops) are involved in determining 
the stability and the flexibility of the overall G-quadruplex structure and can be 
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classified into four groups: diagonal loops, connecting two opposing antiparallel 
strands (Fig.1.3.5 a)), edgewise or lateral loops, connecting two adjacent antiparallel 
strands (Fig.1.3.5 b)), double-chain-reversal or propeller loops, connecting adjacent 
parallel strands (Fig.1.3.5 c)), and V-shaped loops, connecting two corners of a G-
tetrad core in which one supporting column is lacking (Fig.1.3.5 d)). It has also been 
demonstrated that these TTA loops can act as important targets for drug-binding.[57] 
Finally, the G-quadruplex topology can be influenced by the solution environment, 
such as the presence of different metal ions (Na+ or K+).
Fig.1.3.5 Loops topology in G-quadruplex structures. (Adapted from reference [46]) 
1.3.3 Human telomeric DNA 
The human genome contains a lot of sequences able to form G-quadruplex structures. 
[58] Some of these G-rich sequences have been recognized in human telomeric 
DNA, which is involved in the immortalization process of cancer cells [59-64] and 
genetic stability. [65–67] Therefore, it represents a potentially suitable target for 
anticancer strategies.  
Telomeres are non-coding DNA regions located at the end of chromosomes and 
whose function is to preserve chromosomal integrity. In humans and vertebrates 
telomeres consist of repeats of the guanine-rich hexanucleotide motif 
d(TTAGGG)5?-3?, toward the chromosome end. Shortening of the human telomeric 
DNA occurs in normal somatic cells as a function of the replication cycle and leads 
to cell-cycle arrest and eventually apoptosis when a critical length minimum is 
reached. [68] In contrast, cancer cells have evolved mechanisms to maintain telomere 
length, the most common of which is based on the activation of a reverse 
transcriptase called telomerase. The unlimited proliferative potential of cancer cells 
depends on this telomere maintenance mechanism. This enzyme is activated in the 85 
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- 90 % of tumor cells and functions as a reverse transcriptase by adding multiple 
copies of the 5?-d(GGTTAG)-3? motif to the end of telomeres. [69-71] Novel 
antitumor strategies are aimed at interfering with the mechanisms of telomere 
maintenance by targeting telomerase directly according to an enzyme recognition 
process, or indirectly by means of telomere-interacting agents. [72] 
The human telomeres are largely double-stranded DNA sequences, but the terminal 
100-200 nucleotides at the 3? end are generally single stranded. This portion is able 
to easily fold into an intramolecular G-quadruplex arrangement. Optimal telomerase 
activity requires an unfolded single-stranded DNA as substrate, while the formation 
of G-quadruplexes at the end of telomeres prevents the telomerase enzymatic 
process. [73, 74] Therefore, compounds that selectively bind to and stabilize G-
quadruplex structures may interfere with telomere elongation and thus act as 
potential drugs in anticancer therapy. [75, 76]
In general, the development of an efficient and selective drug needs the knowledge 
of the biological target in terms of chemical and biological properties as well as of 
structural information. In this context, human telomeric DNA in its G-quadruplex 
folding is not an easy target, because of the high polymorphism of the G-quadruplex 
structures. [55] 
This high polymorphism can be observed in the crystal and NMR-derived structures 
of human telomeric repeats, obtained both in K+ and in Na+ solution, available in the 
Protein Data Bank (PDB). [12] Since a certain difficulty exists in determining the 
overall fold of the long telomeric sequences present in vivo, the crystal and NMR-
derived structures have been obtained starting from short human telomeric sequences 
with not more than four repeats, such as d[AGGG(TTAGGG)3] referred to as Tel22. 
These sequences in Na+ solution assume a unique structure, referred to as “basket-
type” [77], which presents anti-parallel strands connected by diagonal and lateral 
loops (Fig.1.3.6 a)). 
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Fig.1.3.6 G-quadruplex structures formed by short telomeric sequences. 
Although the cellular environment features both the monovalent cations, K+ is 
largely predominant, and, as a consequence, experiments involving telomeric 
sequences have been usually performed in K+ solutions. Two different G-quadruplex 
structures, named “hybrid-1” [78] and “hybrid-2” [79] (Fig.1.3.6 b)), have been 
determined for short telomeric sequences in potassium solution. It has been 
suggested that both hybrid-1 and hybrid-2 form and coexist in equilibrium in 
potassium solution. [80] A completely different conformation has been found instead 
for these telomeric sequences in the crystal structures solved in presence of 
potassium ion; this conformation is referred to as “propeller-type” or “all-parallel”
(Fig.1.3.6 c)). [81] 
1.3.4 G-quadruplex ligands 
G-quadruplex binders, due to their ability to inhibit telomerase enzymatic activity, 
are now considered potential anti-cancer drugs. The number of identified G-
quadruplex ligands has grown rapidly over the past few years. Extensive efforts have 
been made to establish reliable structure-activity relationships with the aim of 
identifying effective and selective telomerase inhibitors. Some of these ligands have 
been found to stack on the termini G-quartets of the quadruplex (external ?-
a) BASKET b) HYBRID 
c) PROPELLER (ALL PARALLEL)
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stacking), [82] while others interact with quadruplex grooves or external loops 
without any specific ?-stacking interaction with G-quartet bases. [83, 84] 
As common structural features, G-quadruplex ligands generally share a large, flat, 
aromatic surface, and the presence of protonatable side chains. [72] These 
requirements are fulfilled provided that the molecule exhibits both hydrophobic and 
hydrophilic characteristics.
This pharmacophoric model has often been identified in some classical dsDNA 
intercalators, whose derivatives subsequently have been recognized as G-quadruplex 
binders. An interesting example is represented by acridine derivatives (Fig.1.3.7 a)). 
Effective anticancer drugs containing this heterocyclic moiety (such as amsacrine, m-
AMSA; Fig.1.3.7 b)) are generally able to efficiently recognize DNA according to an 
intercalation binding mode.  
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Fig.1.3.7 a) Schematic representation of the acridine skeleton, with the 
relative numbering system; b) structure of amsacrine (m-AMSA) 
However, several studies have shown that by modulating the substitution pattern on 
this aromatic ring system, it is possible to preferentially direct such ligands toward 
G-quadruplex structures. In particular, a series of 3,6-disubstituited [85-87] and 
3,6,9-trisubstituted acridines, [88-91] as well as some compounds characterized by a 
macrocyclic skeleton containing the acridine moiety [92, 93] have been reported as 
efficient G-quadruplex binders endowed with pharmacological anticancer properties.  
In this contest, a great contribution has been made by Neidle and coworkers through 
the design of the 3,6,9-trisubstituted acridine ligand BRACO-19 (Fig.1.3.8), and the 
subsequent resolution of the crystal structure of the complex between BRACO-19 
and the bimolecular human telomeric G-quadruplex of sequence 
d(TAGGGTTAGGGT), obtained in presence of potassium ion (pdb code 3CE5).[54] 
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The crystal structure of this complex features an “all-parallel” G-quadruplex 
arrangement and can be considered as a model of the interaction between 
quadruplexes and acridine ligands. In addition to strong G-quadruplex binding 
ability, BRACO-19 inhibits telomerase enzymatic activity [94] and cancer cells 
proliferation. [95] 
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Fig.1.3.8 Structure of the ligand BRACO-19 
On the other hand, different substitution patterns on the acridine skeleton, for 
example at 2,7 position, have, to date, been poorly investigated as G-quadruplex 
binders, because they apparently do not provide relevant G-quadruplex 
recognition.[96]
1.3.5 Computational investigations of G-quadruplex-ligand complexes
Quadruplex–ligand interactions can be investigated by both experimental and 
computational techniques; in this thesis work we have employed computational 
approaches. In this context, a series of molecular modeling methodologies applied to 
the investigation of G-quadruplex structures and their complexes have been recently 
reviewed by Neidle and Haider [97], highlighting advantages and limitations of these 
approaches. Some problems in simulating G-quadruplexes can arise, indeed, from 
their high structural polymorphism and flexibility as well as from their highly 
charged environment, resulting from the combination of the charges on the 
phosphate groups and on the central ion-containing channel. The absence of a well-
defined binding site is another challenge that must be considered in the 
computational investigation of these molecular systems. However, this review points 
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out that recent improvements in force fields parameters for nucleic acids and 
computational algorithms make possible a more confident application of modeling 
methodologies to G-quadruplex complexes.  
1.3.6 Aim of the work
Acridine ligands have shown the ability to bind and stabilize G-quadruplex structures 
and have received attention as potential anti-cancer drugs. To our knowledge, 
however, 2,7-disubstituted acridine derivatives have, to date, been poorly 
investigated as G-quadruplex binders. Recently, a series of polyaza ligands 
(Fig.1.3.9) have been synthesized, which feature an acridine moiety inserted in an 
open-chain (L1) or macrocyclic (L2 and L3) aliphatic polyamine framework via 
functionalization of the 2- and 7-positions of the heteroaromatic system. These 
ligands enable the exploitation of the effect that a cyclic organization of the aliphatic 
polyamine chain has on the recognition properties for various DNA structures.
Thus, in order to obtain structural information and to elucidate the thermodynamic 
forces that regulate the binding process, we decided to carry out a comprehensive 
study on the binding properties of the three 2,7-disubstituted acridine derivatives (L1, 
L2, and L3, Fig.1.3.9) towards telomeric G-quadruplex structures, and to compare 
them with their respective dsDNA binding profiles. In this thesis work we report the 
detailed computational investigation performed on these molecular systems. [98] 
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Fig.1.3.9 Acridine derivatives (L1, L2 and L3) considered in the computational study.  
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This chapter deals with theoretical bases underlying the computational methods used 
throughout the investigation together with the indication of the software and the 
hardware used. All methodologies are based on the equations of classical physics and 
are related to an MM (Molecular Mechanics) approach to the study of the molecules.
2.1 Hardware 
? Workstation SO Linux Dual Core AMD Opteron 4 processors 
? Distribution: Linux version 2.6.9-42.0.10.ELsmp 
? CPU: i686 
? Processors: 4 
? Perl: 5.008 
? Glibc: 2.3.4 
? Workstation SO Linux Intel Xeon 8 processors 
? Distribution: Linux version 2.6.18-53.1.13.e15 
? CPU: x86_64 
? Processors: 8 
? Perl: 5.008 
? Glibc: 2.5 
? High Performance Computing (HPC) based on Linux cluster 
      FRONT-END 
? Server: 1U E-Rack 4151 
? Processor: Intel Core 2 Duo E6400 2.13 GHz 
? RAM: 1 GB DDR2-667 ECC Reg. 
? Disk-array: 2 x SATAII 500 GB hot-swap RAID1 
? DVDRW: Dual Layer slim 
? 2 x Interface LAN 1 Gbit 
      2 NODES: A002 COMPUTE NODE INTEL DUAL 
? Server: 1U E-Rack 5122 
? 2 x Processor Intel Xeon 5130 DC 2,0 Ghz 4MB 
? RAM: 4 GB DDR2-667 ECC Reg. 
? Hard-disk: SATAII 80 GB 7200 rpm hot-swap 
? DVDROM: slim 
? 2 x Interface LAN 1 Gbit 
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? CINECA HPC IBM P575 Power 6 SP6 
? Model: IBM pSeries 575 
? Architecture: IBM P6-575 Infiniband Cluster 
? Processor Type: IBM Power6, 4.7 GHz 
? Computing Cores: 5376 
? Computing Nodes: 168 
? RAM: 21 TB (128 GB/node) 
? Internal Network: Infiniband x4 DDR 
? Disk Space: 1.2 PB 
? Operating System: AIX 6 
? Peak Performance: 101 TFlop/s 
2.2 Software 
? Schrödinger® Protein Preparation Wizard (protein preparation); 
? Swiss-PdbViewer (protein analysis and homology modeling); 
? BioEdit (protein sequences alignment); 
? ORAC (MD simulations and REM simulations); 
? AMBER9 suite (MD simulations and free energy calculations);  
? Schrödinger® Maestro (building and visualization of molecules); 
? Schrödinger® Glide (molecular docking); 
? Gaussian09 (calculation of the electrostatic potential); 
? APBS (solution of the Poisson Boltzmann equation); 
? Mercury (visualisation and analysis of molecular structures); 
? VMD (visualization and analysis of MD trajectories). 
2.3 Computational methods 
2.3.1 Molecular Docking and Scoring
The computational technique referred to as molecular docking aims to predict the 
optimal mutual orientation resulting from the interaction between different 
molecules, such as two biological targets (i.e. protein-protein interaction) or a ligand 
and a receptor (protein or DNA fragments). [99-101] In this thesis we focused on this 
last approach, trying to find the optimal placement (pose) of small compounds 
(ligands) in the binding site of a biological target (receptor) and to estimate their 
binding affinities. Such a docking experiment requires at least three different 
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elements: the availability of the three-dimensional structure of the biological target, a 
database containing the structures of synthesized molecules or "virtual" compounds 
to test and a computational algorithm. In general, the available algorithms operate in 
two steps: at first (pose generation or docking) they place a ligand into the receptor 
binding site in the appropriate manners for optimal interactions with the 
macromolecules, while in a second stage (pose evaluation or scoring) they evaluate 
the ligand-target interactions in order to estimate the binding affinity by means of 
appropriate scoring functions. In many docking methods, during the pose generation, 
only the ligand is treated as flexible while the structure of the target is kept rigid. 
However, both molecules involved in the interaction are flexible and some docking 
algorithms are now able to take into account the mutual conformational changes 
which occur upon the binding between the ligand and the target. [102, 103] 
The docking algorithms available nowadays are quite reliable in the pose generation 
and are generally able to reproduce the experimental pose of a compound, obtained 
by X-ray crystallography (docking accuracy). The major problem can arise on the 
contrary in the scoring stage, where it is very difficult to obtain an accurate 
prediction of binding affinities for a set of molecules (scoring accuracy). The scoring 
functions of docking algorithms are indeed a fast and simplified estimation of the 
binding free energy related to the ligand affinity: )ln( affinitybinding KRTG ??? .
Three types of scoring functions are now currently employed: 
o Force field based, which use electrostatic and van der Waals interaction 
terms derived from a molecular mechanics force field (FF) as the score, 
sometimes in combination with solvation or entropy terms; 
o Empirical, which use multivariate regression methods to determine 
coefficients of physically motivated structural functions, which contribute to 
the binding free energy, by using a training set of ligand-target complexes 
with experimentally determined binding affinity; 
o Knowledge-based, which use atom pair potentials derived from the analysis 
of structural databases, such as the PDB [12], as the score. 
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2.3.1.1 Glide 
In this thesis work we have used the software Glide [104-106] (Grid-Based Ligand 
Docking with Energetics), developed by Schrödinger® which allows to dock 
"flexible" ligands within the binding site of the “rigid” structure of a known receptor 
(proteins or DNA fragments). The procedure implemented in Glide consists of three 
different steps: protein preparation, grid generation and docking.
The protein preparation is a crucial step for the accuracy of the subsequent docking 
protocol. In this stage the three-dimensional structure of the receptor is partially 
optimized through the neutralization of the amino acids not involved in salt bridges, 
the introduction of hydrogen atoms and the removal of any steric contacts (clashes) 
between the residues.
During the grid generation, the program builds a regular lattice of points around the 
receptor which describe the shape and the properties of the binding site in terms of 
vdW and electrostatic force fields. In this stage two different grids are defined, 
referred to as bounding box or ligand center box or inner box and enclosing box or 
outer box which represent the boxes within which all ligand atoms must be 
contained. The two boxes share a common center (Fig.2.1).
Fig.2.1 Graphical representation of the bounding box (coloured in green) 
and the enclosing box (coloured in purple). In the picture is represented the 
complex between an acridine derivative and a G-quadruplex DNA 
structure, considered in this thesis work.  
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The bounding (internal) box surrounds the area where the centroid of the ligand can 
move during the docking calculation, while the enclosing (external) box, which 
contains the bounding box, defines the region where the program calculates the vdW 
and electrostatic fields and represents the physical space where all the atoms in the 
ligand must be included during the docking. The residues of the receptor that are 
outside the enclosing boxes are not considered in the calculation.  
The docking stage is characterized, in turn, by a series of steps. In a first step 
(conformation generation), Glide makes an exhaustive conformational search within 
the space defined within the enclosing box in order to assess the different 
conformations of a ligand and to eliminate those with high energy, considered 
unsuitable for the binding with the receptor. In this stage, the program treats each 
ligand as formed by a core and a rigid set of "rotamer groups" attached to this core 
by rotatable bonds; the various rotamers are defined as fragments which do not 
contain any rotatable bonds. A set of starting conformations for the "core" are thus 
generated, whose number generally depends on the conformational flexibility of the 
system, and the entire molecule is finally reconstructed by combining together all 
these conformations of the core with the various rotamers previously defined. At this 
point in order to find the best orientation of a ligand within the binding site of the 
receptor, a series of hierarchical filters are applied to the conformations previously 
obtained, according to the following scheme (Fig.2.2). 
Fig.2.2 A schematic representation of the hierarchical filters applied by the 
software Glide.
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After these steps which contribute to the pose generation, the program evaluates the 
affinity of each pose for the binding site (final scoring), using an empirical scoring 
function, the GlideScore or ligand-receptor interaction energy, calculated as the sum 
of molecular mechanics terms which account for hydrophobic, coulombic, vdW 
interactions, interactions with metals and hydrogen bonds. The best poses for a 
ligand, correctly docked into the binding site of the receptor, are finally chosen using 
the value of the E-model, another scoring function which combines the GlideScore 
with the ligand internal strain energy.  
2.3.2 Molecular Dynamics Simulations
Molecular Dynamics (MD) simulation is a powerful computational technique to 
investigate, at the atomistic level, the dynamic behaviour of biological 
macromolecules in solution. This methodology allows the prediction of chemical and 
physical properties of these biomolecules and is currently used in the field of drug-
design. [107, 108] It is essentially based on the assumption of an inter-particle
potential (V), a function of the positions of the nuclei which represents the potential 
energy of the system, and on a stepwise numerical integration of the classical 
Newtonian equation of motion: 
Fi=miai    (eq.1) 
for each atom i in the system. Here mi is the atom mass, ai = d2ri/dt2 its acceleration, 
and Fi the force acting upon it, due to the interactions with other atoms. These forces 
Fi can be derived as the gradients of the potential V with respect to atomic 
displacements: 
),...,,( 21 Nri rrrVF i???      (eq.2) 
Molecular dynamics, based on these “classical” equations, is a deterministic 
technique: given an initial set of positions and velocities, the subsequent time 
behaviour is in principle completely determined. Nowadays, computer technology 
allows to perform routinely large-scale MD simulations of thousands particle 
biomolecular systems even on personal workstations.   
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MD simulations performed in silico are in many respects very similar to real 
experiments performed in a laboratory. First, the macromolecular system has to be 
correctly prepared. Then, through the solution of Newton’s equation of motion, the 
system is equilibrated until its properties no longer change with time. Finally, after 
this equilibration stage, the actual measurement of physical properties is performed, 
in a situation very close to experimental conditions. The result of this computer 
experiment is a trajectory, which specifies the set of molecular conformations 
assumed by the macromolecular system during the simulation as a function of time.  
Typically, many interesting biophysical events occur on a time scale which goes 
from nanoseconds (ns) to milliseconds (ms). In order to obtain reliable results we 
need to simulate the biological system for a comparable time; typical “standard” MD 
simulations are currently carried out on biological systems for a time ranging from ns 
to microsecond (?s). Besides the long time of simulation, when dealing with 
biomolecular systems in solution, due to their polar and highly charged nature, 
another major challenge has to be faced, i.e. the calculation of long-range 
electrostatic interactions. 
In this thesis work, MD simulations have been performed by using the program 
ORAC [109-112] and the AMBER9 suite. [113] Both the program ORAC and 
AMBER9 employ a similar potential function (V) to describe the interaction among 
solute atoms. 
Following the implementation of the force field in the program ORAC, the potential 
V can be written as the sum of two contributions: 
V = Vbonded + Vnonbonded     (eq.3) 
The “bonded” part of the potential (Vbonded) is responsible for the flexibility of the 
system. The “non bonded” term (Vnonbonded) is dominated by electrostatic interactions. 
The interaction bonded potential is a function of the stretching, bending and torsion 
internal coordinates and has the following form: 
torsionbendingstretchingbonded VVVV ???      (eq.4) 
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Its explicit form is given by:  
)]cos(1[)()( 20
2
0 ???? ?? ??????? ???
?
nKKrrKV
dihedralsproperanglesbonds
rbonded      (eq.5) 
where, Kr and K? are the bonded force constants associated with bonds stretching and 
angles bending respectively, while r0 and ?0 are their respective equilibrium values. 
In the torsion potential, Vtorsion, ? is the dihedral angle, while K?, n and ? are 
constants. In addition to this normal or proper torsion potential, in the bonded 
potential, there is another term which takes into account the so-called improper
torsions and has the following form: 
?
?
? ???
dihedralsimproper
torsi nKV )]cos(1[ ???      (eq.6) 
where ? is the improper dihedral angle, while K?, n and ? are constants. 
The “non-bonded” potential can be written as: 
elvdwbondednon VVVV ???? 14     (eq.7) 
where the Vvdw term is the Lennard-Jones potential, given by: 
? ??
ij
ijijijijvdw rBrAV )/()/(
612      (eq.8) 
The term V14 is a nonbonded interaction, typical of biomolecular force fields, 
between two atoms separated by three consecutive bonds; this interaction is 
composed of an electrostatic and a Lennard-Jones term. Finally, the term Vel in eq.7 
includes all long-range electrostatic interactions and is the most difficult to handle in 
computer simulations of charged particles.  
The standard Ewald summation method and its different implementations, such as 
the particle mesh Ewald (PME) procedure or the smooth particle mesh Ewald 
(SPME) method, [114-118] are used both in ORAC and in AMBER9 to treat long-
range electrostatic interactions. These methods give the exact result for the 
electrostatic energy of a periodic system consisting of an infinitely replicated neutral 
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box of charged particles and thus are the natural choice in MD simulations of 
complex molecular systems with periodic boundary conditions (PBC). 
Standard equilibrium simulations of complex biosystems are usually performed, both 
in ORAC and in AMBER9, by using PBC to correctly simulate a macromolecular 
system in an environment similar to the real one and without introducing boundary 
effects.
When using PBC, the macromolecular system is enclosed in a unit cell of suitable 
geometry (box) replicated to infinity by rigid translation in all the three Cartesian 
directions, completely filling the space. The different shapes of the box normally 
employed in MD simulations are cubic or rectangular, truncated octahedral and 
rhombic dodecahedric. The dimension of these simulation cells is very large in order 
to set to zero the interactions among replicated images of the system. Such a system, 
single solvated macromolecule in PBC, is thus representative of dilute solution of 
biomolecules since the solute molecules in the periodic systems can never come 
close to each other, thereby interacting. Moreover, PBC avoid that water molecules 
are in contact with the vacuum, giving rise to boundary effects.
Focusing on the program ORAC, its other features are the use of a reversible and 
symplectic multiple time step integration algorithm (or r-RESPA, reversible 
reference system propagation algorithm) [119-122] for the numerical solution of 
equations of motions and the possibility to perform MD simulations in different 
thermodynamic ensembles, by using the extended Lagrangian (EL) methods to
maintain constant pressure and constant temperature.[123-125] The fundamental idea 
of EL methods is to represent the effect of a suitable external reservoir by adding 
new degrees of freedom to the system. ORAC can perform simulations in the 
microcanonical (NVE), canonical (NVT), isobaric (NPH), and isothermal-isobaric 
(NPT) ensembles. All these advanced computational techniques implemented in the 
program allow very efficient simulations of biomolecular systems.  
2.3.3 Advanced Sampling Methods 
Efficient and extensive sampling is a fundamental requirement for successful protein 
simulations, but large barriers between different local energy minima in rugged free 
energy landscapes of biological systems make it difficult to explore large areas of the 
2. Materials and Methods 
35
conformational space using standard MD simulations at moderate temperatures. In 
general, swaps between these conformers can take, in average, as long as a few 
microseconds.[126] Thus, in a standard MD simulation, the system may remain 
trapped during the whole computationally accessible simulation time in a local 
minimum, and the “rare event” of escaping the trap never happens. To overcome this 
sampling problem, a variety of advanced simulation techniques have been developed; 
one of these is the Replica Exchange Method (REM), also known as Parallel 
Tempering. [127-130] 
2.3.3.1 The Hamiltonian Replica Exchange Method (Hamiltonian REM) as 
implemented in ORAC [112] 
In its standard implementation (Temperature REM), Replica Exchange Method 
employs a set of independent and simultaneous MD simulations of the same system 
at different temperatures (replicas), allowing consecutive simulations (i, i±1) to 
exchange complete configurations of the system at regular intervals and using a 
probabilistic criterion (Fig.2.3).
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Fig.2.3 Typical REM simulation with 8 replicas. Each colour represents a 
process running in parallel. 
Generally, the range of employed temperatures goes from the temperature of interest 
T0 to a higher temperature TM, high enough to accelerate the crossing of local 
conformational barriers and to allow the sampling of metastable conformers. The 
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production of these independent simulations can benefit from the use of large 
clusters of CPUs where the different replicas are performed in parallel. The 
thermodynamical conditions of these simultaneous trajectories are chosen so as to 
span homogeneously the thermodynamic space from the ensemble of interest to a 
different ensemble with enhanced transition rates, where the sampling is ergodic. 
Due to the swapping between different replicas, a trajectory is no longer bound to an 
unique given equilibrium ensemble but can randomly walk in a thermodynamic 
space of different equilibrium conditions, visiting ensembles where an ergodic 
sampling is possible, and then going back to the quasi-ergodic ensemble of interest. 
The gain in sampling efficiency with respect to a series of uncoupled parallel 
trajectories comes from the exchange of information between trajectories, and the 
replica exchange process is the tool by which “information” (e.g. a particular 
configuration) is carried, for example, from a high to a low temperature.  
In this thesis work we employed a more recent version of this computational method, 
the so-called Hamiltonian REM, [131] as implemented in ORAC. [112] In the 
Hamiltonian REM, the same result of an increasing of the temperature is obtained 
through an inverse scaling of the interaction potential energies of the system. In its 
simplest implementation each replica is so characterized by a different potential 
energy, according to the equation: 
)()( XVcXV ii ?      (eq.9) 
where Vi (X) denotes the potential energy of the ith replica and V(X) the original 
potential perceived by the system.  
One of the main advantages of using the Hamiltonian REM, also employed in this 
thesis work, is the possibility to apply the scaling factor ci only to a specific part of 
the potential, weakening only the interactions involving interesting regions of the 
simulated system. This specific approach is referred to as “solute tempering”. Under 
these conditions the portion of interest is defined as "the solute", while the remaining 
regions of the simulated system are referred to as "the solvent".  
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According to this subdivision, the potential energy of a given macromolecular 
system in solution can be written as the sum of different contributions: 
V(X) = V solute (X) + V solute – solvent (X) +V solvent (X)     (eq.10) 
where Vsolute includes all the solute-solute interactions, while the Vsolute - solvent term 
includes the interactions between the solute and the solvent and Vsolvent all the 
solvent–solvent interactions. In this “solute tempering” implementation of the 
Hamiltonian REM it is possible or (1) to scale all the interactions involving the 
solute, according to the equation: 
)().()( XVVVcXV solventsolventsolutesoluteii ??? ?      (eq.11) 
where Vi(X) is the potential of the ith replica, or (2) to proceed to a further 
subdivision of the potential involving the solute and then to scale only specific terms 
of this potential. 
In this second approach, employed in this thesis work, the solute-solute and the 
solute-solvent interactions are treated separately; these two terms are generally 
referred to as intra-solute and inter-solute potentials. In this work, we focused on the 
intra-solute potential, which in turn can be written as the sum of various 
contributions; each of these terms can be scaled in the ith replica according to the 
following equation: 
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The first term of the sum, in the eq.12, collects all the potential terms generating 
“fast” motions: stretching (Vstretching), bending (Vbending) and improper torsional 
interactions (Vimproper?torsion). This term includes also proper torsions involving 
hydrogen atoms (Vhproper?torsion). The second term in eq.12 collects all the other 
proper torsional interactions (Vproper?torsion) and the so-called 1–4 interactions (V14). 
Finally, the third term of eq.12 collects all the nonbonded interactions: the Lennard-
Jones potential (Vvdw) and the electrostatic potential (Velectrostatic). In this context the 
typical choice, also employed in this thesis work, is to set in eq.12 ci1 = 1 for all 
replicas, as there is little advantage for conformational sampling in exchanging 
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configurations involving stiff degrees of freedom such as bendings, stretchings and 
improper torsions. On the other hand, conformational transitions in proteins are 
mainly driven by torsional and non bonded interactions, generating “slow” motions. 
The approach employed in this work was to “heat up” these degrees of freedom by 
scaling the corresponding potential functions in eq.12, by using ci2 < 1 and ci3 < 1. 
2.3.4 Free Energy Methods 
The “free energy methods” are computational tools which allow an accurate 
estimation of the difference in free energy (?Gbinding) between the two biologically 
relevant states involved in the binding process, corresponding to the ligand and the 
macromolecule in their free states (R and L) and to the resulting complex (RL). [132, 
133] This binding free energy is very important in the field of drug discovery since it 
is related to the affinity of a compound, according to: )ln( affinitybinding KRTG ??? . In 
this thesis work ?Gbinding values were computed by the method referred to as 
Molecular Mechanics - Poisson Boltzmann Surface Area (MM-PBSA), [134] as 
implemented in AMBER9. 
2.3.4.1 Molecular Mechanics - Poisson Boltzmann Surface Area (MM-PBSA) method 
This computational approach for the evaluation of ?Gbinding employs a series of 
energy terms calculated on the basis of molecular mechanics and by implicit solvent 
models. In these calculations, it uses a set of conformations, for the ligand and the 
target alone and for their complex, taken from the output of a single MD simulation 
carried out on a target-ligand complex in explicit solvent. An average ?Gbinding is 
thus evaluated combining the values of the free energy of binding calculated for all 
the snapshots taken from the MD trajectory; in this way it is also possible to take into 
account the mutual adaptation ligand-target which occurs during the MD simulation 
and referred to as induced-fit.
The value of ?Gbinding for each snapshot is calculated according to the following 
equation:
?Gbinding = Gcomplex – (Gtarget + Gligand)    (eq.13) 
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where the values of the free energy (G) for the ligand and the target alone and for the 
complex are the sum of different terms. 
For each molecular species involved in the equilibrium, G is given by: 
G = EMM + Gpsolv + Gnpsolv – TS     (eq.14) 
In the eq.14, EMM is in turn the sum of several energy terms calculated on the basis of 
molecular mechanics (Ebond + Eangle + Etorsion + EvdW + Eelectrostatics).
Gpsolv is the polar contribution to the solvation energy of the molecule, which is 
evaluated by applying a model of implicit solvent. In this thesis work, this term was 
calculated through the solution of the Poisson Boltzmann equation (PBE). 
Gnpsolv is the non-polar contribution to solvation energy, which depends on the 
solvent-accessible surface area (SASA), according to the equation: 
Gnpsolv=?SASA+???????eq?????
where ? is the surface tension and ? a coefficient. 
The last term of the eq.14 accounts for the entropic contribution. Here, T is the 
absolute temperature and S is the entropy term calculated with the normal mode 
analysis (NMA). [135] 
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3.1 COMPUTATIONAL INVESTIGATION OF THE KDR DOMAIN 
3.1.1 Molecular Modeling investigation on the closed conformation of the KDR 
domain
The starting coordinates for the KDR domain of the human VEGFR2 were obtained 
from the crystal structure of this target in a complex with a benzimidazole-urea 
inhibitor, refined at 2.05Å resolution (pdb code 2OH4 [16]). This X-ray three-
dimensional structure is the only one, among those available in the PDB for the KDR 
domain, with the A-loop completely solved. This structure lacks, however, a 
fragment belonging to the kinase insert domain (KID) and corresponding to the 
residues ranging from Tyr936 to Tyr994 (according to the 2OH4 numbering system). 
Moreover, this structure, although double phosphorylated in two tyrosine residues 
(Tyr(P)1052 and Tyr(P)1057), has the A-loop in an inhibitory conformation and the 
DFG motif in an “out” orientation.
Computational studies require a suitable starting structure for: (1) the removal of all 
non-protein units, including the inhibitor and all the water molecules, from the 
crystal structure, (2) the selection of only one orientation for these residues (Cys860, 
Cys1043, Leu1067, Glu1156) with two alternative positions emerged from X-ray 
crystallography, (3) the reconstruction of the residues having missing atoms and (4) 
the assignation of the most probable protonation state to the histidine residues 
according to the environment at pH 7 (histidine tautomers with the hydrogen on the ?
or ? nitrogen or double protonated). Moreover, the coordinates of the first residue 
(His814), not completely solved, were removed. All these operations were performed 
by the Schrödinger® Protein Preparation Wizard routine. [136]  
Thus, the three-dimensional structure of the KDR domain employed in the 
computational study begins with the residue Cys815 and ends with the residue 
Asp1169, according to the 2OH4 numbering system.  
In a second stage of this protein preparation, we tried to solve the problem 
concerning the missing region in the crystal structure 2OH4 and corresponding to 57 
residues of the KID. It has been demonstrated [15] that the removal of these residues 
is necessary for protein crystallization but has no effect on the intrinsic kinase 
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activity. This region is, however, structurally important because it connects two ?-
helices in the C-terminal lobe and maintains the overall architecture of the KDR 
domain. Starting from these observations, we decided to reconstruct this not solved 
region (residues 936-994) by modifying the primary sequence of the KDR domain 
through the introduction of a short loop connecting the two solved ends, instead of 
modeling the whole KID. This reconstruction was performed by using the routine 
Build Loop of Swiss-PdbViewer. [137] 
We introduced into the three-dimensional structure several loops of different length, 
in order to find the best “hinge” between the two solved ?-helices in the C-terminal 
lobe. We chose to introduce only alanine loops because of the small and mostly inert 
methyl functional group of this residue. The best result was found by inserting a loop 
formed by five residues, according to a set of geometrical and energetic parameters 
provided by the routine Build Loop, such as a count of the clashes (number of bad 
contacts or H-bonds), an energy information (computed with a partial 
implementation of the GROMOS96 force field [138]) and a mean force potential 
value (computed from a "Sippl-like" mean force potential [139]).  
After the introduction of this alanine loop into the three-dimensional structure, the 
number of residues of the KDR domain has changed compared to the starting crystal 
structure 2OH4. As a consequence, we decided to renumber the overall protein 
starting from 1, corresponding to the residue Cys815 in the structure 2OH4, to 303, 
corresponding to Asp1169. The sequence of this partially reconstructed structure is 
displayed in the Fig.3.1.1.
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10 20 30 40 50
....|....| ....|....| ....|....| ....|....| ....|....|
KDR_domain 1 CERLPYDASK WEFPRDRLNL GKPLGRGAFG QVIEADAFGI DKTATCRTVA 50
60 70 80 90 100
....|....| ....|....| ....|....| ....|....| ....|....|
KDR_domain 51 VKMLKEGATH SEHRALMSEL KILIHIGHHL NVVNLLGACT KPGGPLMVIV 100
110 120 130 140 150
....|....| ....|....| ....|....| ....|....| ....|....|
KDR_domain 101 EFCKFGNLST YLRSKRNEFV PYAAAAAYKD FLTLEHLICY SFQVAKGMEF 150
160 170 180 190 200
....|....| ....|....| ....|....| ....|....| ....|....|
KDR_domain 151 LASRKCIHRD LAARNILLSE KNVVKICDFG LARDIXKDPD XVRKGDARLP 200
210 220 230 240 250
....|....| ....|....| ....|....| ....|....| ....|....|
KDR_domain 201 LKWMAPETIF DRVYTIQSDV WSFGVLLWEI FSLGASPYPG VKIDEEFCRR 250
260 270 280 290 300
....|....| ....|....| ....|....| ....|....| ....|....|
KDR_domain 251 LKEGTRMRAP DYTTPEMYQT MLDCWHGEPS QRPTFSELVE HLGNLLQANA 300
...
KDR_domain 301 QQD 303
Fig.3.1.1 Primary sequence of the KDR domain after the introduction of 
the alanine loop in the C-terminal lobe; this alanine loop is highlighted in 
red.  
According to this new numbering system employed for the KDR domain, the alanine 
loop, introduced into the KID, starts with the residue Ala123 and ends with the 
residue Ala127. The A-loop starts with the DFG motif, which corresponds to the 
residues Asp178, Phe179, Gly180 and ends with the APE motif, which corresponds 
to the residues Ala205, Pro206 and Glu207. The two phosphotyrosines, Tyr(P), into 
the A-loop, identified as X in the above primary sequence, correspond to the residues 
Tyr(P)186 and Tyr(P)191. Some important correspondences with the crystal 
structure 2OH4 are listed in the Table.3.1.1. 
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Table.3.1.1 KDR important regions and correspondences between the new numbering 
system and the 2OH4 numbering system. One letter code is employed for amino acids; 
the two phosphotyrosines Tyr(P) are indicated as Yp.  
Region Primary sequence
Residue 
number
Structure 
2OH4  
Gly-rich loop GRGAFG 25-30 839-844 
?3 strand VAVKMLK 49-55 863-869 
?C-helix HSEHRALMSELKILIHI 60-76 874-890 
hinge region FCKFGN 102-107 916-921 
catalytic loop HRDLAARN 158-165 1024-1031 
DFGLARDIYpKDPDYpVRKGDARLPLKWMAPE 178-207 1044-1073 
DFGLA (magnesium binding loop) 178-182 1044-1048 A-loop 
YpKDPDYp (activation segment) 186-191 1052-1057 
Since the original crystal structure 2OH4 is unusual among kinase structures having 
the A-loop in an inhibitory conformation although double phosphorylated, we also 
decided to investigate the dynamic behaviour of the corresponding structure with the 
two phosphotyrosines mutated into tyrosine residues (Tyr186 and Tyr191). This 
unphosphorylated form of the KDR domain is actually present in vivo when the 
whole receptor is inactivated. This three-dimensional structure of the target in the 
inactive conformation was chosen as the starting point for the investigation of the 
opening mechanism in the KDR domain. 
3.1.2 Building of the open conformation of the KDR domain 
In order to obtain structural information on the other limit conformation of the KDR 
domain (i.e. the active and DFG-in conformation whose 3D coordinates are not 
available), we decided to build a “chimeric” open structure of this target by using a 
homology modeling approach. We built a three-dimensional model for the KDR 
domain in its active conformation, starting from the observations that (1) the active 
state of the kinase domain is essentially invariant among RTKs and that (2) the main 
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difference between the two limits conformations is the orientation of the A-loop. [35, 
36]
We used the structure of the kinase domain of the insulin receptor, crystallized in its 
active conformation and with the DFG motif in the “in” form (pdb code 1IR3 [38]), 
as template. The primary sequences of the KDR domain and of the kinase domain of 
the insulin receptor were aligned using ClustalW [140] (BLOSUM62 similarity 
matrix) multiple global alignment, implemented in BioEdit. [141] The resulting 
alignment is shown in the Fig.3.1.2.  
10 20 30 40 50
....|....| ....|....| ....|....| ....|....| ....|....|
KDR_domain CERLPYDASK WEFPRDRLNL GKPLGRGAFG QVIEADAFGI DKTATCRTVA 50
1IR3 --SSVFVPDE WEVSREKITL LRELGQGSFG MVYEGNARDI IKGEAETRVA 48
60 70 80 90 100
....|....| ....|....| ....|....| ....|....| ....|....|
KDR_domain VKMLKEGATH SEHRALMSEL KILIHIGHHL NVVNLLGACT KPGGPLMVIV 100
1IR3 VKTVNESASL RERIEFLNEA SVMKGFT-CH HVVRLLGVVS KG-QPTLVVM 96
110 120 130 140 150
....|....| ....|....| ....|....| ....|....| ....|....|
KDR_domain EFCKFGNLST YLRSKRNEFV PYAAAAAYKD FLTLEHLICY SFQVAKGMEF 150
1IR3 ELMAHGDLKS YLRSLRPEAE ----NNPGRP PPTLQEMIQM AAEIADGMAY 142
160 170 180 190 200
....|....| ....|....| ....|....| ....|....| ....|....|
KDR_domain LASRKCIHRD LAARNILLSE KNVVKICDFG LARDIXKDPD XVRKG-DARL 199
1IR3 LNAKKFVHRD LAARNCMVAH DFTVKIGDFG MTRDIX-ETD XXRKGGKGLL 191
210 220 230 240 250
....|....| ....|....| ....|....| ....|....| ....|....|
KDR_domain PLKWMAPETI FDRVYTIQSD VWSFGVLLWE IFSLGASPYP GVKIDEEFCR 249
1IR3 PVRWMAPESL KDGVFTTSSD MWSFGVVLWE ITSLAEQPYQ GLSNEQVLK- 240
260 270 280 290 300
....|....| ....|....| ....|....| ....|....| ....|....|
KDR_domain RLKEGTRMRA PDYTTPEMYQ TMLDCWHGEP SQRPTFSELV EHLGNLLQAN 299
1IR3 FVMDGGYLDQ PDNCPERVTD LMRMCWQFNP KMRPTFLEIV NLLKDDLHPS 290
310
....|....| ....|....
KDR_domain AQQD------ --------- 303
1IR3 FPEVSFFHSE ENKGDYMNM 309
Fig.3.1.2 Sequence alignment between the partially modified KDR domain and the kinase domain 
of the insulin receptor (crystal structure 1IR3). Amino acid residues conserved or similar in the 
two sequences are highlighted in blue and in cyan, respectively. The A-loop is highlighted in red. 
The phosphotyrosines of the A-loop, Tyr(P), are identified by X in the two sequences.  
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This sequence alignment revealed a high degree of similarity for the A-loop in the 
two proteins (Fig.3.1.2): (1) same number of residues between the two common end 
motifs, DFG and APE, (2) same position of the two phosphotyrosines (X in the 
primary sequences) of the KDR domain compared with two, of the three, 
phosphotyrosines of the insulin receptor and (3) sequence identity in the residues at 
the beginning (VKI-DFG) and at the end (WMAPE) of the A-loop. 
Starting from these results, we built a “chimeric” structure of the KDR domain in its 
active conformation, in which the coordinates for the backbone of the A-loop were 
obtained from the crystal structure 1IR3. The remaining residues for the “chimeric” 
structure were taken from the previously modified crystal structure of the KDR 
domain in the closed and DFG-out conformation (pdb code 2OH4), with the alanine 
loop inserted into the KID. 
Although, from a structural superposition of the two three-dimensional structures 
(closed and DFG-out conformation of the KDR domain and open and DFG-in
conformation of the InsR kinase domain) other elements show a slight different 
orientation, we decided to not introduce any other artificial element in this 
“chimeric” structure of the KDR domain, but to investigate its reliability and the 
possible reorganization of the different structural elements by using standard MD 
simulations.   
In detail, the homology model was generated first by inserting the A-loop of the 
crystal structure 1IR3, between the motif VKI (underlined in yellow in the Fig.3.1.2) 
and the motif APE, into the previously modified structure of the KDR domain in its 
closed conformation, and then by modifying the side chains of the different amino 
acids according to the KDR primary sequence using the program Swiss-PdbViewer 
(MUTATE command). [137] Similarly to the closed conformation of the KDR 
domain, we modified the two phosphotyrosines of the A-loop into tyrosine residues 
(Tyr186 and Tyr191) to avoid the not clear effect of the phosphorylation. 
3.1.3 Molecular Dynamics Simulations setup 
Explicit solvent MD simulations on the previous modified structures of the KDR 
domain have been performed by using the program ORAC, [109, 112] the AMBER 
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ff03 [142] force field and the TIP3P water model. [143] The force field parameters 
for the two non-standard phosphotyrosines (Tyr(P)186 and Tyr(P)191) were adapted 
from the work of Homeyer et al. [144] The phosphorylated and unphosphorylated 
structures were then solvated by approximately 9100 water molecules in a rhombic 
dodecahedron box with periodic boundary conditions. The systems were initially 
equilibrated during a 100 ps NPT simulation at T = 300 K and P = 1 atm, where 
constant pressure was obtained using a modification of the Parrinello-Rahman 
Lagrangian [110] and temperature control was achieved using a Nosé thermostat. 
[125] The cell side was equilibrated at an average value of 77Å. The Ewald method 
with the smooth particle mesh algorithm [117] was used to compute electrostatic 
interactions. The grid spacing in each dimension of the direct lattice was ~ 1.2Å, 
whereas the Ewald convergence parameter was set to 0.43Å?1. Electro-neutrality was 
enforced using respectively a uniform positive and negative charge density 
background equalizing the -1 e and +3 e excess negative and positive charges on the 
phosphorylated and unphosphorylated structures. A multiple time-step r-RESPA 
algorithm [119, 121] with a potential subdivision specifically tuned for proteins was 
used for integrating the equations of motion, with time-steps 9.0, 3.0, 1.5 fs for non 
bonded and 0.75, 0.375 fs for bonded interactions. [109, 110, 118] The last 
configurations, obtained from these simulations performed on the unphosphorylated 
open (DFG-in) and closed (DFG-out) conformations of the target, were used as 
starting points for the production runs performed in the same conditions for 5 ns. 
3.1.4 Hamiltonian Replica Exchange (Hamiltonian REM) simulations 
The last configuration obtained from the previous equilibration of 100 ps carried out 
on the crystallographic derived structure of the KDR domain, in the closed and DFG-
out conformation and with the two tyrosines phosphorylated (Tyr(P)) in the A-loop, 
was used as a starting point for the REM simulations performed by using the 
program ORAC. The Hamiltonian REM [131] implementation of the REM algorithm 
was adopted, in which the replicas of the system differ in their potential energy 
function V. In the Hamiltonian REM formalism, the potential of the ith replica is 
given by Vi = ciV0 where V0 is the original potential of the system and ci is a 
multiplicative factor that varies with the replica number. In this study, the application 
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of this methodology, in the “solute tempering” version, was limited to the residues 
belonging to the A-loop (the so-called “solute”), also including some residues 
located before the important DFG motif (residues 178-180) to better investigate its 
dynamic behaviour. The “solute” in our Hamiltonian REM simulations included the 
residues between Ile176 and Glu207 of the KDR domain (I1042-E1073 according to 
2OH4 numbering). In detail, we applied the multiplicative factors only to intra-loop 
potential terms (torsional and non bonded interactions are weakened; paragraph 
2.3.3.1). Other interactions, including those between the A-loop and the rest of 
system, are not affected by scaling factors. In this context, we used the knowledge of 
the fact that the A-loop is the most flexible region of the target, while the 
conformational changes in other region are more limited. 
In detail, the multiplicative factors were chosen such that the effective temperatures 
of the 42 replicas are distributed over the temperature range from 300 K to 3000 K, 
with temperature progression according to the scheme given in ref [131]. Each 
replica was equilibrated with a different potential Vi for 5.4 ps in the NPT ensemble. 
Then, exchanges were attempted every 270 fs. Replica exchanges were (on average) 
accepted with a 60 % probability, leading to an average time of ~ 450 ps between 
two consecutive accepted exchanges. The system was simulated for 4.5 ns, for a total 
simulation time of 189 ns. 
3.1.5 Hot simulations 
Because of the high computational demand of the REM methodology, we also 
performed some targeted simulations, referred to as “hot simulations”, at the highest 
effective temperature Ti = T0/ci employed in the previous Hamiltonian REM 
(3000K). With such simulations we tried to gain a qualitative understanding of the 
A-loop opening mechanism in the KDR domain, exploiting the accelerated sampling 
due to the intra-loop potential scaling. It has been shown that the A-loop is a highly 
flexible portion of the kinase domains, such that the closed and open loop 
configurations are partially stabilized by salt bridges and hydrophobic contacts with 
the rest of the protein. [34] We exploit this fact by altering the loop-loop interactions 
only, while maintaining all the other interactions unaltered. We remark that older 
studies using “hot” accelerated simulations of kinases were conducted heating up all 
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the system and applying harmonic restraints to atoms outside the kinase A-loop. 
[145] This approach, however, leads to weaker also solvent-solvent and hydrophobic 
interactions, especially between the A-loop and the rest of the protein. Our approach, 
on the contrary, permits to fully observe the effect of hydrophobicity on the 
conformational landscape of the A-loop and on the opening/closing mechanism. 
In detail, we performed 16 targeted “hot simulations”, starting from the closed and 
DFG-out conformation of the KDR domain in the non phosphorylated form, to avoid 
the unclear effect of the phosphate groups in the movement of the A-loop. All the 
“hot simulations” were performed for 10 ns. In these simulations, at variance with 
the Hamiltonian REM simulations discussed in the previous paragraph, the side 
chains of Asp160 and Arg164 were included in the definition of the “solute”, to 
prevent the formation of loop-protein salt bridges, as it will be explained in detail in 
paragraph 4.1.4.
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3.2 MODELING INVESTIGATION OF DOUBLE HELIX AND G-
QUADRUPLEX DNA STRUCTURES IN COMPLEX WITH ACRIDINE-BASED 
POLYAMINE LIGANDS 
3.2.1 Solution studies [98] 
The protonation states of ligands L1, L2 and L3 (Fig.3.2.1) were investigated by 
potentiometric and 1H NMR measurements. In all three cases, the diprotonated form 
[H2L]2+ (L = L1, L2 or L3) is the most abundant species in aqueous solution at 
physiological pH. 1H NMR investigations indicated that the two first protonation 
steps occur on the methylated nitrogen atoms in the case of L1, and on the central 
nitrogen atoms of the tetra-amine chain in the case of L2 and L3. 
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Fig.3.2.1 Acridine-based polyamine ligands considered in this thesis work 
(L1, L2 and L3) with the correct protonation state at physiological pH. 
3.2.1.1 Acridine derivatives binding to dsDNA [98] 
Because the affinity of a ligand for DNA can be affected by the DNA sequence, the 
binding process of the three ligands was preliminarily monitored towards 
oligonucleotides of different base composition, namely poly(dA-dT) and poly(dG-
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dC). It was found that the binding to the tested DNA sequences is essentially equal, 
thus confirming a lack of sequence selectivity.  
All the experimental studies performed in solution allowed us to draw a picture of 
the dsDNA binding pattern for these acridine derivatives (L1, L2 and L3). Although 
all ligands efficiently interact with DNA, the nature of the side chains plays a key 
role in the binding mode. In detail, experimental results seem to suggest a 
preferential, non-intercalative binding mode for L3. In this case, the driving force is 
mainly the electrostatic interaction of the charged ligand with the nucleic acid, which 
promotes DNA precipitation, observed under the experimental conditions employed. 
In contrast, L1 and L2 showed similar behaviour, thus suggesting a more favorable 
balance of the ??? interactions between the acridine moiety and the base pairs, on 
the one hand, and the H-bond and salt bridge interactions, supported by the charged 
substituents, on the other.
It is well known that small macrocycles such as L2 and L3, which contain a rigid 
aromatic moiety in their structures, often adopt bent conformations. As a 
consequence, one could easily propose that the insertion of the acridine moiety 
between DNA base pairs would be more difficult in the case of macrocycles L2 and 
L3 than for L1. Surprisingly, whereas no such intercalation seems to be present with 
L3, L2, which contains an overall shorter cyclic aliphatic chain, is still able to 
interact with dsDNA in a manner similar to the acyclic L1.Thus, to gain a more in-
depth insight, we decided to carry out a modeling investigation.  
3.2.1.2 Acridine derivatives binding to G-quadruplex forming sequences [98]  
The potential interaction of tested ligands (L1, L2 and L3) with G-quadruplex 
structures was evaluated by monitoring both the stabilization and the induction of G-
quadruplex structures assumed by telomeric sequences. Experimental studies clearly 
illustrated how the stabilization efficiency of the three novel ligands is modulated by 
the nature of their side chains. In particular, L2 appeared to be the most active in 
stabilizing a G-quadruplex structure, followed by L3 and L1. Thus, the similarity 
between L1 and L2 in the dsDNA binding properties is not conserved when the 
target sequence assumes a G-quadruplex structure.  
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Other solution studies were performed in order to determine if this interaction 
reflects any ability of the new tested compounds to induce the formation of G-
quadruplex structures, starting from an oligonucleotide containing only two human 
telomeric repeats (2GGG). In particular, this sequence can form G-quadruplex 
structures only by pairing two or four strands, thus leading to dimeric or tetrameric 
structures. The experimental results showed that, among the tested acridine 
derivatives, only L2 was able to induce the folding of 2GGG into a tetrameric G-
quadruplex structure, thus confirming it as the most efficient G-quadruplex binder. 
The induction of the tetrameric DNA arrangement for the 2GGG telomeric sequence 
correlates well with recent crystallographic data showing a related trisubstituted 
acridine bound to a G-quadruplex [54] with two dimeric units held together by one 
drug molecule stacked on the terminal G-quartets. Thus this crystallographic 
structure (pdb code 3CE5 [54]) was considered a suitable model for our 
computational studies. 
3.2.2 Computational studies 
3.2.2.1 Building of ligands and DNA fragments 
The binding capacity of H2L12+, H2L22+ and H2L32+ (Fig.3.2.1) toward the telomeric 
G-quadruplex structure of sequence d(TAG-GGT-TAG-GGT) and toward double-
helical DNA oligonucleotides (10-mers) of base composition poly(dG-dC) was 
investigated. Ligand molecules and dsDNA containing CG or GC intercalative 
binding sites were built by the Build module of Maestro v. 8.5. [146] Starting 
coordinates for the tetrameric G-quadruplex were obtained from the biological unit 
of the BRACO-19-d(TAG-GGT-TAG-GGT) complex X-ray crystal structure (PDB 
code 3CE5 [54]). The three ligands were built in the ionized state in order to simulate 
their behavior under physiological conditions. 
3.2.2.2 Docking and Molecular Dynamics simulations 
Docking calculations were performed using Glide [147] with the DNA structures 
kept fixed in their original conformation throughout the docking procedures. Selected 
poses of the ligand-target (both dsDNA and G-quadruplex) complexes were 
submitted to MD simulation for 10 ns in explicit solvent, and the root mean square 
3. Experimental section 
52
deviation (RMSD) values of the complexes were monitored as a function of 
simulation time. 
The atomic electrostatic charges of the ligands were calculated by means of the 
RESP procedure, [148] that is, fitting them to an electrostatic potential calculated at 
the HF/6-31G* level of theory using Gaussian09 software. [149] General Amber 
force fields (GAFF) parameters were then assigned to the ligands by the 
antechamber module implemented in AMBER9 suite. [113] Each complex was 
immersed in a truncated octahedral box, the edges of which were located 10Å from 
the closest atom of the DNA fragments, and which contains ~4700 water molecules 
for the poly(dG-dC) dsDNA oligonucleotides, and ~5800 water molecules for the G-
quadruplex complexes. To maintain neutrality in the system, 16 and 38 K+
counterions were added to the solvent bulk of the dsDNA-water complexes and to 
the solvent bulk of the G-quadruplex-water complexes, respectively. In the case of 
the G-quadruplex structure, according to X-ray data, [54] 4 K+ ions were placed 
along the axis within the central core of the complex, midway between each G-tetrad. 
The positively charged K+ counterions were added to the solvent bulk in order to 
maintain the consistency with the crystallization conditions and to perform the 
simulation in a uniform K+ ionic environment. Before starting the MD simulations, 
an energy minimization of the complexes was performed by setting a convergence 
criterion on a gradient of 0.01 kcal mol-1 Å-1. Water shells and counterions were then 
equilibrated for 40 ps at 300 K, after which 10 ns of MD simulation in an isothermal-
isobaric ensemble was performed without any restrain on each complex. The ff03 
version of the AMBER force field was used for the DNA fragments and the 
counterions, [142] whereas the TIP3P model [143] was employed to explicitly 
represent water molecules. In the production runs, the ligand–DNA fragment systems 
were simulated in periodic boundary conditions. The van der Waals and short-range 
electrostatic interactions were estimated within a 10 Å cutoff, whereas the long-range 
electrostatic interactions were assessed by using the particle mesh Ewald method, 
[117] with 1 Å charge grid spacing interpolated by fourth-order B-spline, and by 
setting the direct sum tolerance to 10-5. Bonds involving hydrogen atoms were 
constrained by using the SHAKE algorithm [150] with a relative geometric tolerance 
for coordinate resetting of 0.00001 Å. Berendsen’s coupling algorithms [151] were 
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used to maintain constant temperature and pressure with the same scaling factor for 
both solvent and solutes, and with the time constant for heat-bath coupling 
maintained at 1.5 ps. The pressure for the isothermal–isobaric ensemble was 
regulated by using a pressure relaxation time of 1 ps in the Berendsen’s algorithm. 
The simulations of the solvated complexes were performed using a constant pressure 
of 1 atm and a constant temperature of 300 K. A time step of 2 fs was used in the 
simulations, which were carried out with the AMBER9 program suite. [113] 
3.2.2.3 MM-PBSA calculations of ?Gbinding
Free energies were calculated by using the MM-PBSA method, as implemented in 
the AMBER9 program suite. [113] The electrostatic contribution to the solvation free 
energy was calculated with the nonlinear Poisson Boltzmann method as implemented 
in the adaptive Poisson Boltzamm solver (APBS) [152] program through the 
AMBER/iAPBS interface. The hydrophobic contribution to the solvation free energy 
was determined with terms dependent on solvent-accessible surface area. In these 
calculations, we used a solvent probe radius of 1.4Å to define the dielectric 
boundary, a physiological salt concentration of 0.154M to calculate the effect of salt 
on the free energies, and dielectric constants of 1.0 and 80.0, respectively, for the 
solute and the surrounding solvent. Atomic charges for DNA fragments and ligands 
are the same as those employed in the MD simulations. For atomic radii, we applied 
the PARSE [153] parameter set. PARSE radii (PARameters for Solvation Energy) 
have been properly optimized for implicit solvent models. In general, the PARSE 
radii are on average 0.2Å less than the corresponding van der Waals radii. In the case 
of the G-quadruplex structures, the cations (K+) present within the negatively 
charged central channel were also explicitly included in the calculation. The K+ ion 
radius was kept at 2.025Å, based on a previous study. [57] Free energies were 
estimated by collecting snapshots every 40 ps during the last 4 ns of the 10 ns MD 
simulations.  
The entropic contribution was estimated with the normal mode analysis (Nmode 
[135] module of AMBER9 suite) which computes vibrational, rotational, and 
translational entropies. The snapshots were minimized in the gas phase for a 
maximum number of 1 × 105 cycles to give an energy gradient of 1 × 10-4 kcal mol-1
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Å-1. These minimized structures are then used to estimate the translational, rotational, 
and vibrational entropies at 300 K. Because of the extensive computational 
requirement, the normal mode analyses were performed by considering snapshots 
collected every 200 ps during the last 4 ns of the 10 ns MD simulations.
Molecular graphics were produced with Mercury [154] and Visual Molecular 
Dynamics (VMD). [155]  
4. Results and Discussion 
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4.1 COMPUTATIONAL INVESTIGATION OF THE KDR DOMAIN 
4.1.1 Preliminary computational studies 
The human VEGFR2 is a receptor tyrosine kinase involved in many biological 
functions, such as angiogenesis and vasculogenesis, and recognized as an attractive 
target in anticancer therapies. In particular, its inhibition can be achieved through 
highly potent small organic compounds targeting different conformations of the 
cytoplasmic kinase domain. However, the structural data now available for the KDR 
domain of the human VEGFR2 are limited compare to other protein kinases. First of 
all, there are no available experimental data for the active conformation of this target 
and all the X-ray solved 3D structures of its inactive conformations collected in the 
PDB are incomplete. The only structure that has the coordinates for the entire A-loop 
is 2OH4 [16], although with high B-factors associated with the corresponding atoms. 
Here, the A-loop is in an inhibitory conformation and the DFG motif in an “out” 
orientation.
Thus, in order to investigate at the atomistic level a possible path involving the 
transition from the closed to the open conformation of the target, and to sample some 
possible intermediate conformations to employ in a structure-based drug discovery 
study, in a preliminary step we tried to solve the gaps in the experimental data and 
fully characterize the two limit conformations through the use of molecular modeling 
tools.
Affinity of inhibitors for the activate or inactivate kinase form could dictate the open 
or closed conformation of the A-loop, thus making the different conformations of 
kinases different drug targets in drug discovery projects and in this view making the 
conformational sampling of particular relevance.
Because of the unusual phosphorylation state of the tyrosine residues of the A-loop 
in the crystal structure 2OH4, computational investigations were carried out on the 
not phosphorylated state of the protein; similarly, the structure of the KDR domain in 
the open conformation obtained by the homology modeling procedure, described in 
the experimental section, was considered in its unphosphorylated state. 
Due to incomplete and not fully reliable crystallographic data available for the KDR 
domain in the starting structure 2OH4 (very high B-factors values and disorder in the 
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electron density-maps) and in order to assess the effect of our computational 
modifications on the overall stability of the target, we performed on these two limit 
conformations 5 ns of standard MD simulations in explicit solvent. These 
simulations also allowed the optimization of the “chimeric” structure obtained by 
homology modeling for the open and DFG-in conformation. All MD simulations 
were performed on the protein structures in their unligated form and no ligands were 
included in the simulations. The two optimized structures can then be used in the 
rational design of selective type-I, type-II and type-III kinase inhibitors. 
4.1.2 Characterization of the closed and open conformations of the KDR domain 
through MD simulations
Fig.4.1.1 shows the root mean square deviation (RMSD) of the atoms belonging 
respectively to the overall kinase domain and to the A-loop, calculated with respect 
to the corresponding atoms in the initial closed and open conformations. RMSD was 
monitored throughout MD simulations and evaluated by taking into account only the 
C??atoms. In general, these values show a good thermal stability for the overall 
structure of the KDR domain in both the inactive (top panel) and active (bottom 
panel) conformations (black solid lines a) in the Fig.4.1.1), while a higher mobility 
can be observed for the A-loop (red solid lines a) in the Fig.4.1.1). It is worth noting 
the A-loop is more flexible in the inactive conformation than in the open structure 
where the coordinates for the A-loop were taken from a different kinase domain. 
This confirms the reliability of the model built for the open and DFG-in
conformation and shows that this structure is preserved throughout the simulation. 
Moreover, the figure Fig.4.1.1 clearly shows that the A-loop is the most diverse 
region between the inactive and active conformations of the target (black and red 
dotted lines b) in both top and bottom panel in the Fig.4.1.1).
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Fig.4.1.1 RMSD evaluated by taking into account only the C? as a function of time. Top and bottom 
panels refer to the inactive (DFG-out) and active (DFG-in) KDR conformation, respectively.  
Top: RMSD values evaluated for the closed conformation of the target with respect to a) the starting 
closed 2OH4 conformation (solid line) and b) to the starting open “chimeric” conformation (dotted 
line). Red and black lines refer to RMSD values computed for the A-loop atoms and the entire KDR 
domain, respectively.  
Bottom: RMSD values evaluated for the open and DFG-in conformation of the target with respect to 
a) the starting open “chimeric” conformation (solid line) and b) to the starting closed 2OH4 
conformation (dotted line). Red and black lines refer to RMSD values computed for the A-loop atoms 
and the entire KDR domain, respectively.  
The visual inspection of the MD trajectories showed that the two structures remain in 
their starting (closed or open) conformation throughout the simulations (Fig.4.1.2). A 
rearrangement can, however, be observed for the ?C-helix in the N-terminal lobe and 
for the A-loop, which is indeed the most flexible region of the target. In particular, 
the ?C-helix, with the same coordinates in the two starting conformations, assumes 
after a partial and opposite rotation two different orientations, which can be referred 
to as ?C-OUT and ?C-IN (Fig.4.1.2).   
a)
a)
b)
b)
a) a)
b)
b)
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Fig.4.1.2. Ribbon representation of the closed and DFG-out (top) and open and DFG-in (bottom) 
conformations of the KDR domain at the beginning (left) and after (right) 5 ns MD simulation. The 
important regions of the protein are highlighted with different colours.  
4.1.2.1 Analysis of MD trajectories
A detailed analysis of the behaviour of the A-loop region during the two MD 
simulations showed that the highly conserved DFG motif did not change its starting 
orientations (respectively DFG-out and DFG-in) and we did not observe the so-
called “DFG flip”. This result suggests that the time scale for this flip is much longer 
than the time of the standard MD simulations.
The dihedral angle (? and ?) values of the residues belonging to the DFG motif 
(Asp178, Phe179, Gly180; D1044 F1045 G1046 in 2OH4 numbering) were 
monitored throughout the simulations. These angles show characteristic values that 
remain constant during the simulations and can thus be used to define the two limit 
conformations of the A-loop. These values are reported in the Ramachandran plots in 
Fig.4.1.3.
0 ns MD simulation 5 ns MD simulation 
a)
b)
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Fig.4.1.3 Ramachandran plots for the ? and ? angles of the residues Asp178, Phe179 and 
Gly180 monitored during the two MD simulations performed on: a) the closed and DFG-out
conformation and b) the open and DFG-in conformation of the KDR domain. Top: schematic 
representation of the? and ? angles. 
In detail, in the DFG-out conformation (Fig.4.1.4), the aromatic ring of Phe179 
(F1045) points toward the ATP binding cleft e no hydrogen bonds are formed 
between the three residues (Asp178, Phe179, Gly180; D1044 F1045 G1046) and 
other residues of the protein which contribute to the stabilization of the DFG motif in 
this orientation. 
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Fig.4.1.4 Representation of the DFG-out (top) and DFG-in (bottom) conformations resulting from the 
two standard 5ns MD simulations. The backbone of the A-loop is coloured in red.  
In the DFG-in conformation, on the contrary, the residues of the DFG motif are 
involved in a network of H-bonds strengthened by salt bridges (Fig.4.1.5) with the 
two highly conserved residues Lys52 (K866) and Glu69 (E883) of the N-terminal 
lobe, which also play an important role in the kinase catalytic mechanism. The salt 
bridge between Lys52 (K866) and Glu69 (E883) also contributes to anchor the ?C-
helix in its ?C-IN position.  
Additional hydrogen bonds are formed between:  
? the CO of the backbone of Asp178 (D1044) and the residue His158 (H1024), 
belonging to the highly conserved HRD motif of the catalytic domain; 
? the NH of the backbone of Phe179 (F1045) and Glu69 (E883); 
? the CO of the backbone of Phe179 (F1045) and the NH of Ala182 (A1048). 
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Moreover, in the DFG-in conformation, the side chain of Phe179 (F1045) is buried 
in the hydrophobic pocket, adjacent to the ATP binding site, which is formed by the 
side chains of the residues Ile72 (I886), Leu73 (L887), Val82 (V896), Leu151 
(L1017), Ile176 (I1042) and Ala182 (A1048). These hydrophobic residues can be 
considered part of the hydrophobic network (“hydrophobic spine”) which has been 
recognized as a stabilizing element of the active conformations of the kinase 
domains. [32, 34] 
Fig.4.1.5. Network of interactions which contribute to the stabilization of the DFG motif 
in the “in” orientation. Residues of the DFG motif are represented in yellow. H-bonds are 
indicated with dotted green lines; hydrophobic residues are represented in purple. 
The detailed analysis of the remaining portion of the A-loop in the two limit protein 
conformations allowed the determination of other interactions which can be 
responsible for the stabilization of the A-loop in its active or inactive state. 
The analysis of the MD trajectory for the DFG-out structure shows that the 
conformation of the A-loop seems to be mainly stabilized by a series of hydrogen-
bonds, strengthened by salt bridges, involving residues belonging to the A-loop and 
to other portions of the protein (inter-loop H-bonds). In addition several hydrogen-
bonds inside the A-loop are formed and disrupted during the MD simulation (intra-
loop H-bonds). Residues involved in inter-loop H-bond contacts are shown in 
Fig.4.1.6.
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Fig.4.1.6 Conformation of the KDR domain sampled during the MD 
simulation, with the network of external interactions which stabilize the A-
loop in its inactive state. Hydrogen-bonds are indicated with dotted green 
lines. 
The interaction involving the charged groups of Asp184 (D1050) and Arg164 
(R1030) is very stable throughout the simulation, while the salt bridge formed 
between Asp160 (D1026) and Arg198 (R1064) is less stable during the MD 
trajectory, although the charged residues remain in close proximity (Fig.4.1.7). Both 
these interactions can act as constraint to the free movements of the A-loop and can 
anchor the loop in its closed conformation, thus preventing the sampling of 
intermediate conformations for the target. An additional constraint to the flexibility 
of the A-loop can also be recognized in the inter-loop interaction involving the side 
chain of Tyr186 (Y1052), a residue which undergoes phosphorylation, and the 
positively charged region formed by the residues Arg26 (R840) and Lys55 (K869).  
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Fig.4.1.7. Monitoring of Arg164 (R1030) - Asp184 (D1050) and Asp160 
(D1026) - Arg198 (R1064) distances during the MD simulation carried out on 
the closed and DFG-out conformation of the KDR domain. The distance is 
evaluated between the centroids of the functional groups involved in the polar 
interaction. 
On the contrary, in the active and DFG-in conformation of the KDR domain, the A-
loop is oriented in order to allow the access of an ATP molecule into the active site. 
During the MD trajectory hydrogen-bonds are in turn formed and broken, the only 
intra-loop stable interaction that is maintained throughout the MD simulation 
involves the side chains of Arg183 (R1049) and Asp188 (D1054). However, apart 
from these polar interactions, the open conformation of the KDR domain seems to be 
mainly stabilized by hydrophobic interactions as recently highlighted for other kinase 
domains. [32, 34] 
The results obtained from these standard MD simulations are not surprising because 
the transition between the two limit conformations of the target involves a complete 
rearrangement of the region around the binding site and happens on a time scale 
much longer than that usually employed for standard MD. In this view the transition 
from the inactive to the active (or vice versa) A-loop conformation can be indeed 
considered a “rare event”. In general, rare events are processes that occur 
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infrequently due to dynamical bottlenecks that separate stable states and their 
observation require either very long simulation times or the employment of a 
sampling method. Standard MD studies in explicit solvent can, in fact, access only a 
limited time scale (about 100 ns), while large-scale conformational rearrangements 
occur on a longer time scale. Thus, in order to overcome such limitation in the 
sampling efficiency of standard MD, we used the sampling method referred to as 
Hamiltonian REM. Our aim was to investigate at atomic details a possible opening 
mechanism involving the KDR domain, starting from the inactive and DFG-out
conformation.  
4.1.3 Hamiltonian REM simulations on the crystallographic derived structure of 
KDR domain
Hamiltonian REM simulations in explicit solvent were performed starting from the 
inactive 2OH4 derived structure of the KDR domain bearing the two tyrosines of the 
A-loop in their phosphorylated states: Tyr(P)186 (Yp1052) and Tyr(P)191 (Yp1057). 
In these simulations we gradually weakened (scaled) only the torsional and non 
bonded interactions involving the residues of the A-loop (residues 176-207; 1042-
1073); the other interactions, including those involving simultaneously residues 
inside and outside the A-loop were not affected by the scaling factors. Scaling only 
the intra-loop interactions, in particular, permits to fully observe both the effect of 
hydrophobicity and the effect of the inter-loop interactions on the conformational 
landscape of the A-loop and on the opening/closing mechanism. 
These REM simulations aimed also to test the effect of the 2OH4 unusual 
phosphorylation on the efficiency of sampling. Results from these simulations 
confirmed the importance of the dephosphorylation of the inactive conformation in 
order to allow a free movement of the A-loop and the sampling of intermediate 
conformations. The strong interaction between the negative charged phosphate group 
of the Tyr(P)186 (Yp1052) and the positive charged region generated by the side 
chains of both Arg26 (R840) and Lys55 (K869) in the N-terminal lobe is not affected 
by scaling factors in the different replicas, and locks the A-loop in its inactive 
conformation, thus acting as a real external hook (Fig.4.1.8). This polar interaction is 
also present in the replica performed at the highest effective temperature (T = 3000 
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K) and is not affected by the accelerated motion of the A-loop resulting from the 
scaling of the intra-loop potential terms.  
Fig.4.1.8 A conformation of the KDR domain observed in the highest 
replica employed in Hamiltonian REM simulations. The strong interaction 
involving the side chains of the residues Tyr(P)186 (Yp1052), Arg26 
(R840) and Lys55 (K869) is highlighted. It is worth noting that the side 
chains of the two phosphotyrosines are distorted as a result of the scaling 
of the intra-loop potential terms. 
Fig.4.1.9 shows the probability distribution of the distances between the residues 
involved in the aforementioned strong polar interaction (Tyr(P)186 (Yp1052), Arg26 
(R840) and Lys55 (K869)), in the highest replica of Hamiltonian REM simulations. 
These distributions reveal, in fact, that even at T = 3000 K the two monitored 
distances assume values centered to 3.5Å and 4.5Å, corresponding to strong 
interactions, thus demonstrating that these salt bridges play a key role in anchoring 
the A-loop in its closed conformation.  
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Fig.4.1.9 Structural data obtained from the highest replica of the Hamiltonian REM simulations 
performed on the phosphorylated inactive and DFG-out conformation of the KDR domain (effective 
temperature, T=3000 K). Black line: distribution of the distances between the phosphorus atom (P) of 
Tyr(P)186 (Yp1052) and the centroid of the guanidinium group of Arg26 (R840). Red line: 
distribution of the distances between P of Tyr(P)186 (Yp1052) and the centroid of the ?-amino group 
of Lys55 (K869). 
Combining the results obtained from the previous simulations (standard MD and 
Hamiltonian REM) clearly emerged that a series of external constraints can interfere 
with the free movement of the A-loop and do not allow the sampling of intermediate 
conformations for the target. In particular, we have identified as possible hooks, the 
salt bridges involving the residue pairs Arg164 (R1030) - Asp184 (D1050) and 
Asp160 (D1026) - Arg198 (R1064), in addition to the polar interaction between the 
phosphotyrosine Tyr(P)186 (Yp1052) and the positive region formed by the side 
chains of Arg26 (R840) and Lys55 (K869). In this context, the removal of the 
phosphate groups from the inactive structure greatly reduces the last interaction.
4.1.4 Hot (3000 K) simulations to explore a possible opening mechanism, starting 
from the closed conformation of the KDR domain 
In order to reduce the computational cost of a Hamiltonian REM simulation and to 
investigate the effect of the previously identified external salt bridges on the opening 
mechanism involving the A-loop, 16 independent “hot (10 ns) MD simulations” were 
performed starting from the closed and DFG-out conformation of the KDR domain 
in the non phosphorylated form. In these “hot simulations”, the interactions involving 
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the salt bridges between the residue Asp160 (D1026) - Arg198 (R1064) and Arg164 
(R1030) - Asp184 (D1050) were weakened, in addition to the intra-loop interactions 
also scaled in the previous Hamiltonian REM simulations. Among these 16 “hot 
simulations”, 12 remain close to the initial closed and DFG-out conformation 
throughout 10 ns. Instead, the other 4 “hot simulations” have a different behaviour 
and the system approaches, in different ways, to the open conformation during the 10 
ns.
The RMSD values, evaluated by taking into account only the C??atoms of the A-loop 
from their reference positions in the open and DFG-in and closed and DFG-out
conformations (same references as in Fig.4.1.1) are shown as a function of the time 
In detail, in the Fig.4.1.10 are shown the 4 “hot simulations” (coloured in green, 
yellow, blue and black) in which the A-loop reaches an almost open conformation, 
plus another “hot simulation” (coloured in red) taken as representative of the 12 “hot 
simulations” in which the A-loop maintains the closed and DFG-out conformation.  
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Fig.4.1.10 Conformational sampling observed during 5 independent 10 ns “hot simulations”. Top: 
RMSD evaluated for the C? atoms of the A-loop with respect to the corresponding atoms in the open 
DFG-in conformation as a function of the simulation time. Bottom: RMSD evaluated for the C? atoms 
of the A-loop with respect to the corresponding atoms in the starting closed DFG-out conformation as 
a function of the simulation time. 
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The trend of RMSD for the black “hot simulation” gets away from the reference 
DFG-out conformation (bottom panel in Fig.4.1.10), while approaches to the 
reference DFG-in conformation (top panel in Fig.4.1.10), thus indicating that the 
conformation of the target at the end of this simulation is the one closer to the open 
state of the KDR domain. For this black “hot simulation”, representative snapshots 
were taken at 500 ps intervals; the superposition of these frames (Fig.4.1.11) clearly 
points out that the removal of potential external constraints, obtained by scaling the 
salt bridges, makes it possible to sample a wide range of intermediate conformations 
for the A-loop. 
Fig.4.1.11 Sampling of the A-loop conformations during one “hot 
simulation”; snapshots were sampled at 500 ps intervals. In red is coloured 
the A-loop in the starting DFG-out conformation; in blue is coloured the 
conformation of the A-loop sampled in the last snapshot of the “hot 
simulation”. 
The visual analysis of the black “hot simulation” trajectory showed that Tyr186 
(Y1052 in 2OH4) rapidly loses its interaction (already weakened by the absence of 
the phosphate group) with the positively charged region formed by the side chains of 
Lys55 (K869) and Arg26 (R840) and, as a consequence, the A-loop undergoes a 
rapid conformational rearrangement. However, the movement of the A-loop is also 
promoted by the weakening of the two external salt bridges involving the residues 
Asp160 (D1026) - Arg198 (R1064) and Arg164 (R1030) - Asp184 (D1050). It is 
worth noting that, in the first 5 ns of the black “hot simulation”, the movement of the 
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A-loop involves also a partial rotation of the DFG motif which passes from the DFG-
out to an almost DFG-in conformation (Fig.4.1.12). 
Fig.4.1.12 Conformations of the DFG motif sampled during the black “hot 
simulation”. Snapshots are coloured in chronological order on a rainbow 
scale with red and blue indicating respectively the first (DFG-out) and the 
last (almost DFG-in) conformation sampled during the trajectory. The 
DFG-in conformation of the “chimeric”, homology-built, structure is 
coloured in grey.
Anyway, as it clearly emerges from the Fig.4.1.12, we did not observe a complete 
flip of the DFG motif. It is worth noting that the conformation reached by the DFG 
motif in the first 5 ns of the black “hot simulation” (coloured in blue in the 
Fig.4.1.12), is quite stable and is maintained throughout the remaining 5 ns. A deeper 
inspection of the blue almost DFG-in conformation showed that the Phe179 (F1045) 
side chain results buried in a hydrophobic pocket formed by the side chains of the 
residues Leu73 (L887), Val83 (V897), Val98 (V912) and Val100 (V914), which is 
different from the hydrophobic pocket observed for the DFG-in conformation 
(Fig.4.1.13). Moreover, this almost DFG-in conformation seems to receive a further 
stabilization from a salt bridge between the CO of the backbone of Phe179 (F1045) 
and the highly conserved residue Lys52 (K866), which in turn is hydrogen bonded to 
the residue Glu69 (E883).
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Fig.4.1.13 Superposition of the blue almost DFG-in conformation sampled 
during the black “hot simulation” and the DFG-in conformation of the 
“chimeric” homology-built structure (coloured in grey). Hydrophobic 
residues which surround the Phe179 (F1045) side chain of the DFG motif 
in the two conformations are coloured green and purple. The residue Leu73 
is common to the two hydrophobic regions.
It is worth noting that even the complete opening movement of the A-loop, and thus 
the sampling of the open and DFG-in limit conformation, is prevented by this new 
identified network of hydrophobic residues which interferes with the “DFG flip”. 
Finally, the visual analysis of the black “hot simulation” trajectory highlights only a 
slight rotation of the ?C-helix in the N-terminal lobe with respect to its starting 
orientation.
For the other three “hot simulations”, over the four in which the system seems to 
evolve towards the open conformation (Fig.4.1.10 lines yellow, blue and green), the 
visual analysis showed a slightly different behaviour compared to that observed in 
the black “hot” MD. In particular, we observed a reduced rotation of Phe179 
(F1045), whose side chain interacts with the new identified hydrophobic pocket.
4.1.5 Conclusions 
In this thesis work the closed and open conformations of the KDR domain have been 
initially characterized by means of standard MD simulations. The reconstructed A-
loop region in the active conformation is structurally similar to known kinase 
4. Results and Discussion 
71
domains: with respect to the inactive conformation, the ?C-helix is rotated towards 
the ATP-binding site and the A-loop shows smaller oscillations around the active 
orientation. In order to investigate the opening mechanism of the A-loop, a 
Hamiltonian REM simulation and a series of targeted “hot simulations” have been 
performed starting from the inactive and DFG-out conformation of the KDR domain. 
This approach identified the phosphorylated tyrosines (Tyr(P)186 (Yp1052) and 
Tyr(P)191 (Yp1057)) and the salt bridges involving the residues Asp160 (D1026) - 
Arg198 (R1064) and Arg164 (R1030) - Asp184 (D1050) as the main responsible of 
the loop stability in its inactive conformation; weakening these interactions, the A-
loop has been able to sample, in a few nanoseconds, conformations that are 
intermediates between the inactive and the active one. The complete rotation of the 
A-loop, and thus the sampling of the open DFG-in conformation, however, requires a 
hydrophobic barrier to be overcome. Such a barrier is due to the positioning of the 
Phe179 (F1045) side chain of the DFG motif into a hydrophobic pocket, located near 
to that one observed in the open DFG-in conformation. In any case, a major result 
emerging from the computational investigation performed on the KDR domain, is the 
identification of a stable conformational state for the DFG motif, in which the 
Phe179 (F1045) side chain is buried in a not previously identified hydrophobic 
pocket. Indeed, this conformation, that we have called almost DFG-in, can be 
considered a possible intermediate state of the opening mechanism of the KDR 
domain and it can be very useful in the rational design of inhibitors for this target. 
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4.2 MODELING INVESTIGATION OF DOUBLE HELIX AND G-
QUADRUPLEX DNA STRUCTURES IN COMPLEX WITH ACRIDINE-BASED 
POLYAMINE LIGANDS 
4.2.1 Acridine derivatives binding to double stranded DNA - Docking and MD 
simulations  
The binding mode of the diprotonated species of L1, L2 and L3 towards dsDNA was 
investigated by docking procedures followed by 10 ns MD simulations, with an 
explicit treatment of the aqueous environment.  
MD simulations allowed an optimization of the complexes resulting from docking 
calculations. Double-helix oligonucleotides (10-mer) of base composition poly(dG-
dC) were investigated considering both CG and GC intercalative binding sites. In this 
study we decided to investigate only the base composition poly(dG-dC) for 
oligonucleotides because experimental studies of the binding process of the three 
ligands to oligonucleotides of defined base composition, namely poly(dA-dT) and 
poly(dG-dC), showed a lack of sequence selectivity. [98] 
For all MD simulations, the root mean square deviation (RMSD) of the complexes 
was monitored vs. the simulation time (Fig.4.2.1a and Fig.4.2.1b). 
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Fig.4.2.1 dsDNA/L RMSD value, evaluated for all non hydrogen atoms, as a function 
of time during the recorded MD trajectories: (a) ligand molecule lodged in the CG 
intercalative binding site (blue = L1, yellow = L2 and red = L3), (b) ligand molecule 
lodged in the GC intercalative binding site (blue = L1, yellow = L2 and red = L3).  
RMSD values showed a different behavior for the three ligands in both the 
intercalative binding sites, CG and GC. The same results have emerged from the 
structural comparison of the complexes resulting from MD simulations (Fig.4.2.2). 
All these results largely corroborate the solution studies, as the three ligands feature 
different binding modes towards the poly-G-poly-C double helix. [98] For the open-
chain ligand L1, the interaction can be described as properly intercalative both in the 
case of the CG site, as well as for the GC site. In all situations the adduct was 
stabilized by additional H-bond contacts involving the terminal protonated nitrogen 
atoms and the carbonyl oxygen atom belonging to cytosine and guanine units 
(Fig.4.2.2a) or the phosphate groups (Fig.4.2.2b). In fact, the planar acridine moiety 
of L1 can be easily lodged between the base pairs, unhindered by the pendant arms, 
which, on the contrary, can be set in the grooves. Moreover, the RMSD values 
evaluated as a function of time during the recorded MD trajectories (Fig.4.2.1a and 
Fig.4.2.1b) denotes that the L1-poly-G-poly-C adducts are quite stable, and they are 
not disrupted during the 10 ns simulation time. 
b)
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Fig.4.2.2 Results of the modeling procedures (docking and MD) for the adducts formed 
by diprotonated forms of L1, L2 or L3 and poly-G-poly-C dsDNA. Results were 
obtained by starting from docking in a CG intercalative binding site - (a) L1, (c) L2, (e) 
L3 - and in a GC intercalative binding site - (b) L1, (d) L2, (f) L3. Atoms involved in 
hydrogen bonding are evidenced by light gray circle. 
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On the other hand L3, most likely hindered by the bent conformation adopted by its 
macrocyclic structure, seems to fail the intercalation and gives rise to groove 
binding, interacting mainly through hydrogen bonds between its protonated nitrogen 
atoms and the polyphosphate DNA backbone (Fig.4.2.2e/f). After 10 ns MD 
simulation, the DNA double helix is almost completely rebuild, and no trace of the 
CG or GC intercalative site remains. 
As far as L2 is concerned, it shows an intermediate behaviour between L1 and L3. In 
spite of its rather rigid and strained bent conformation, which is generally considered 
unsuitable for the stereochemical requirement of a classical DNA intercalator, 
modeling studies give evidence of stable conformations for the L2-DNA adduct 
(Fig.4.2.2c), in which the macrocycle is able to give rise to simultaneous ?-? and H-
bonding interactions. Indeed, L2 behaves as a multifunctional ligand towards DNA 
by virtue of its small size. Thus, the presence of the shorter ethylene spacers in place 
of propylene units featured in L3 appears to be essential for obtaining a correct 
match between the binding sites of L2 and the nucleobases.  
4.2.2 Acridine derivatives binding to double stranded DNA - MM-PBSA investigation
A further characterization of the different binding modes has been achieved through 
the estimation of the relative free energies for the three ligand-dsDNA complexes by 
using the Molecular Mechanics Poisson-Boltzmann Surface Area (MM-PBSA) 
approach. This postprocessing method, employed in the evaluation of the Gibbs free 
energies of binding, works on a set of structures collected from MD simulations 
(some representative snapshots, used in the free energy estimation, are shown in 
Fig.4.2.3).
In this study, for the evaluation of the electrostatic contribution to the solvation free 
energy, we used a methodology able to solve the Poisson Boltzmann equation in the 
non-linearized form, which is more suitable to treat highly charged molecules such as 
DNA. It is noteworthy to underline that the MM-PBSA results, reported in Table.4.1, 
are in agreement with the thermodynamic parameters obtained by solution-phase 
studies, [98] showing the higher intercalative ability of L1 and L2 with respect to L3. 
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Fig.4.2.3 Representative snapshots extracted from the MD simulation, performed on the adduct 
formed by the diprotonated form of L2 and poly-G-poly-C dsDNA in a CG intercalative binding 
site, and employed in the free energy estimation by using the MM-PBSA approach  (for detail, 
paragraph 3.2.2.3). 
Table.4.1 Gibbs free energy values (in kcal/mol) calculated by using the MM-PBSA 
approach for adducts formed between ligands (L1, L2, L3) and dsDNA. 
[a] CG intercalative site
[b] GC intercalative site
Ligands 
?Hcalc[a]
kcal/mol 
??Scalc[a]
kcal/mol 
?Gcalc[a]
kcal/mol 
?Hcalc[b]
kcal/mol 
??Scalc[b]
kcal/mol 
?Gcalc[b]
kcal/mol
L1 -33.10 -27.90 - 5.20 -35.53 -30.47 - 5.06 
L2 -32.00 -23.00 -9.00 -19.98 -22.06 2.08 
L3 -16.33 -25.18 8.85 -20.12 -25.77 5.65 
4. Results and Discussion 
77
4.2.3 Acridine derivatives binding to G-quadruplex forming sequences - Docking and 
MD simulations
The orientations resulting from MD simulations carried out on selected poses of L1, 
L2 and L3 in complex with the G-quadruplex obtained from docking calculations 
using as target the 3D coordinates of the crystal structure 3CE5 [54] are shown in 
Fig.4.2.4. The root mean square deviation (RMSD) of the G-quadruplex/L 
complexes was monitored vs. the simulation time for all the three adducts (Fig.4.2.5). 
All these adducts remained quite stable during the MD. 
Fig.4.2.4 Results of MD simulations of the adducts formed by the 
diprotonated species a) L1, b) L2, and c) L3 with G-quadruplex structure 
formed by the 2GGG oligonucleotide. Hydrogen bonds are evidenced by 
green lines; interacting and no interacting DNA monomers (tube 
representation) are coloured in light blue and grey, respectively. 
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Fig.4.2.5 G-quadruplex/L RMSD value, evaluated for all non hydrogen atoms, as a 
function of time during the recorded MD trajectory (blue = L1, yellow = L2 and red = 
L3).
All ligands insert into the tetrameric form of the G-quadruplex, between the 3’-end 
G-tetrad belonging to one G-quadruplex dimer and the 5’-end of the other, in a 
manner similar to that shown by the very effective G-quadruplex ligand BRACO-19 
present in the X-ray crystallographic complex structure. [54] However, the acridine 
moieties of L2 and L3 give rise to stronger ?-? interactions with the 3’-end G-tetrad 
than in the case of L1, the acridine system of which shows the most significant 
deviation from the expected parallel position (16° between the involved planes 
versus 3° and 3.5° for L2 and L3, respectively). Moreover, all ligands cause, to 
varying degrees, a rotation of one dimeric G-quadruplex unit relative to the other. 
Using the BRACO-19-G-quadruplex complex as a reference, and considering the 
dihedral angle formed between 3’- and 5’-end G-tetrads, a 1°, 3° and 9° twist 
(Fig.4.2.6, ?? = ?ligand – ?BRACO-19) is observed for L2, L3 and L1, respectively.
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Fig.4.2.6 Dihedral angle formed between 3’- and 5’-end G-tetrads of a) L1, 
b) L2 and c) L3 G-quadruplex complexes and ?? values evaluated using 
the BRACO-19/G-quadruplex complex [54] as a reference (?? = ?ligand – 
?BRACO-19).
The analysis of the L1-DNA complex shows that both ?-stacking and H-bonding 
interactions involve only one dimer, whereas both the G-quadruplex units are 
simultaneously bound by L2 and L3 (Fig.4.2.4). As far as L2 and L3 are concerned, 
their binding modes seem similar, with both ligands interacting by ?-stacking with a 
guanidine residue of the 5’-end G-tetrad, and by H-bonding with a phosphate group 
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of the other dimer (Fig.4.2.4 b and c). However, compared with L3, L2 causes a less 
significant disruption of the TATA tetrad, also present at the 3’- and 5’-end interface 
in the biological unit of the BRACO-19-DNA complex. In particular, only one 
adenine residue is considerably shifted from its original position, and, at the same 
time, the carbonyl group of a thymine residue gives rise to an additional H-bond 
interaction with a protonated nitrogen of the ligand, thus exerting a significant role in 
the stabilization of the adduct (Fig.4.2.4 b). However, in the case of the L3 complex, 
both the aforementioned adenine and thymine residues are in a different position, and 
no additional H-bond contacts are established. 
Altogether, the observations derived from the modeling procedures support the quite 
surprising results obtained from the solution studies, [98] which show evidence that 
the bent conformations of L2 and L3 do not prevent G-quadruplex recognition.
4.2.4 Acridine derivatives binding to G-quadruplex forming sequences - MM-PBSA 
investigation
Following the same procedure used for the adducts formed between the three ligands 
(L1, L2 and L3) and dsDNA, the binding free energy values for the complexes with 
G-quadruplex were obtained by MM-PBSA calculations (Table.4.2). The obtained 
results indicate that the binding affinity decreases in the order L2 > L3 > L1, in 
agreement with the reported solution studies. [98] In the evaluation of the Gibbs free 
energies we employed a set of structures collected from MD simulations (some 
representative snapshots, used in the free energy estimation, are shown in Fig.4.2.7).  
Table.4.2 Gibbs free energy values (in kcal/mol) calculated by using the MMPBSA approach 
for adducts formed between ligands (L1, L2, L3) and G-quadruplex. 
Ligands 
?Hcalc 
kcal/mol 
??Scalc 
kcal/mol 
?Gcalc
kcal/mol 
L1 -39.11 -29.51 - 9.60 
L2 -40.15 -23.61 -16.54 
L3 -35.58 -22.11 -13.47 
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Fig.4.2.7 Representative snapshots extracted from the MD simulation, performed on adduct 
formed by the diprotonated form of L2 and G-quadruplex DNA, and employed in the free 
energy estimation by using the MM-PBSA approach (for detail, paragraph 3.2.2.3). 
4.2.5 Conclusions 
The new 2,7-substituted acridine derivatives L1, L2, and L3 show an unusual trend 
in their binding patterns toward canonical double-helical DNA and non canonical G-
quadruplex structures. The DNA recognition profile of L1 is in line with the 
expectation: it binds to dsDNA through a pure intercalative process and poorly 
recognizes G-quadruplex structures. Ligand L2 features a small macrocyclic 
framework which is generally expected to adopt a rather bent and rigid conformation, 
usually not prone to intercalative interactions with DNA. However, in spite of this, 
L2 binds to dsDNA almost as well as the open-chain ligand L1, and it shows the best 
performance toward a G-quadruplex. Distinctly, ligand L3, characterized by the same 
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cyclic structure of L2, but with longer and more flexible propylene spacers, should, 
in principle, be able to adopt a planar conformation more readily. Nevertheless, it is 
unable to intercalate into dsDNA, nor can it induce G-quadruplex structures. As 
pointed out by our molecular modeling studies, the better performance of L2 relative 
to that of L3 and the open-chain ligand L1 can be attributed entirely to its particular 
conformation and dimensions, which establish an optimal match with both dsDNA 
and the tetrameric G-quadruplex structure. These results indicate how important it is 
to set up simultaneous combinations of interactions of various kinds between DNA 
and ligand in order to reach an optimal binding efficiency, thus effectively opening 
new possibilities for the design of novel selective DNA binders. [98] 
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Synthesis, Biological Evaluation and Docking Studies of Casuarine Analogues:
Effects of Structural Modifications at Ring B on Inhibitory Activity Towards
Glucoamylase
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We report the total synthesis of a series of pyrrolizidine ana-
logues of casuarine (1) and their 6-O-α-glucoside derivatives.
The synthetic strategy is based on a totally regio- and stereo-
selective 1,3-dipolar cycloaddition of suitably substituted
alkenes and a carbohydrate-based nitrone. We also report
the evaluation of the biological activity of casuarine and its
derivatives towards a wide range of glycosidases and a mo-
Introduction
Iminosugars are very attractive carbohydrate mimics in
which the endocyclic oxygen atom is replaced by the more
basic, trivalent nitrogen atom.[1] In their protonated form,
iminosugars resemble the transition state or intermediate
generated during the hydrolysis reaction catalysed by glyco-
sidases, key hydrolytic enzymes involved in many physiolog-
ical functions. Since the discovery of the inhibitory proper-
ties of iminoalditols towards glycosidases, they have re-
ceived increasing attention as diagnostic compounds as well
as tools for the investigation of the structures, functions and
catalytic mechanisms of carbohydrate-processing en-
zymes.[2,3] Furthermore, given the important role of glyco-
sidases and glycosyltransferases in controlling the structures
and functions of carbohydrates at the cell surface, competi-
[a] Laboratory of Molecular Modeling Cheminformatics & QSAR,
Department of Pharmaceutical Sciences, Laboratory of Design,
Synthesis and Study of Biologically Active Heterocycles (Het-
eroBioLab), University of Florence,
Via Ugo Schiff 6, 50019 Sesto Fiorentino, Firenze, Italy
Fax: +39-055-4573780
E-mail: claudia.bonaccini@unifi.it
paola.gratteri@unifi.it
[b] Department of Chemistry “Ugo Schiff”, Laboratory of Design,
Synthesis and Study of Biologically Active Heterocycles (Het-
eroBioLab), University of Florence,
Via della Lastruccia 3-13, 50019 Sesto Fiorentino, Firenze, Italy
Fax: +39-055-4573531
E-mail: francesca.cardona@unifi.it
[c] Laboratory of Glycochemistry and Asymmetric Synthesis
(LGSA), Swiss Institute of Technology (EPFL),
Batochime, 1015 Lausanne, Switzerland
Supporting information for this article is available on the
WWW under http://dx.doi.org/10.1002/ejoc.201000632.
View this journal online at
wileyonlinelibrary.com © 2010 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim Eur. J. Org. Chem. 2010, 5574–55855574
lecular modeling study focused on glucoamylase (GA) in
which the binding modes of the newly synthesized com-
pounds within the enzyme cavity are investigated. The re-
sults highlight the prominent structural features of casuarine
and its derivatives that make them selective glucoamylase
inhibitors.
tive inhibitors of these classes of enzymes are potential anti-
diabetes, anti-viral and anti-cancer agents.[1,2] Recently,
interesting immunosuppressive activities have been discov-
ered for this class of compounds.[4] In the past 40 years,
more than 100 polyhydroxylated alkaloids have been iso-
lated from plants and microorganisms[5] with structures that
include polyhydroxylated piperidines, pyrrolidines, indolizi-
dines, pyrrolizidines and nortropanes. For instance, the pi-
peridine alkaloid 1-deoxynojirimycin (DNJ, Scheme 1), pre-
pared first by Paulsen et al. in 1967[6a] and then isolated
from a species of Moris (Moraceae),[6b] was found to
strongly inhibit α-glucosidases.[5a] N-Alkylated derivatives
of DNJ have found applications as anti-diabetic drugs (i.e.,
Miglitol, Glyset) or anti-HIV agents (Glycovir, SC
49483).[2a] The indolizidine alkaloid (+)-lentiginosine
(Scheme 1) was isolated in 1990 from the leaves of Astraga-
lus lentiginosus and was found to inhibit amyloglucosid-
ases.[7] Its non-natural enantiomer (–)-lentiginosine was re-
cently discovered to possess proapoptotic activity towards
tumoral cells.[8] Castanospermine (Scheme 1), isolated in
1981 from the seeds, leaves and barks of Castanospermum
australe and in 1988 from the seeds, leaves and barks of
Alexa sp.,[5a] and its ester and salt derivatives are able to
inhibit tumour growth and metastasis.[9]
Casuarine (1, Scheme 2) and its 6-O-α-glucoside, casuar-
ine-6-O-α-glucopyranoside (2, Scheme 2), have been iso-
lated from the bark of Casuarina equisetifolia L. (Casua-
rinaceae) and from the leaves of Eugenia jambolana Lam.
(Myrtaceae).[10] We recently reported that casuarine (1) is
able to inhibit a human maltase-glucoamylase (MGAM,
Casuarine Analogues
Scheme 1. Glycosidase inhibitors.
EC 3.2.1.20) more strongly than the pseudo-tetrasaccharide
acarbose (Scheme 1) currently on the market as an anti-
diabetic drug (Glucobay, Precose) and thus has promise for
the development of novel anti-diabetic drugs.[11]
Table 1. Structures and inhibition activities (IC50) of compounds 1–11 towards glucoamylase from aspergillus niger.
[a] For compounds with an inhibition percentage less than 90% at 1 m concentration, the IC50 values were not determined, and the
percentage inhibition is reported.
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Scheme 2. Casuarine and its 6-O-α--glucoside.
Our total synthesis of casuarine (1) and its 6-O-α-gluco-
side (2) took advantage of a complete stereoselective
nitrone cycloaddition strategy with Tamao–Fleming oxi-
dation and selective α-glucosylation as the key steps.[11]
Glucoamylase (1,4-α--glucan glucohydrolase, GA; EC
3.2.1.3; glycoside hydrolase family GH15, www.cazy.org) is
an exo-hydrolase that catalyses the removal of glucose units
from the non-reducing end of starch and related oligosac-
charides. The hydrolytic reaction, which preferentially oc-
curs at α-1,4 linkages, proceeds with inversion of configura-
tion at the anomeric carbon atom. Glucoamylases are also
able to hydrolyse α-1,6 linkages, but the specific activity is
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only 0.2% with respect to α-1,4 hydrolysis.[12] The interest
in glucoamylase is related to its use in the industrial pro-
duction of bioethanol, glucose and fructose syrups.[13]
Furthermore, given the presence of these enzymes in a wide
variety of organisms and their quite simple obtainment in
a pure form, GA has been extensively studied as a model
for other members of the glycosyl hydrolase family.[14]
In this paper we report the total synthesis of the pyrroliz-
idine analogues of casuarine 4, 6, 7 and 11 (see Table 1), all
bearing the same stereochemical pattern at the more substi-
tuted five-membered ring A as that of casuarine, and their
6-O-α-glucoside derivatives 3, 5 and 8–10. We also report
the evaluation of the inhibitory activities of compounds 1–
11 towards a wide range of commercially available glycosid-
ases and a molecular modelling study on glucoamylase
(GA) from Aspergillus awamori as a result of the selective
inhibitory activity towards GA shown by the tested com-
pounds.
Results and Discussion
Synthesis
The general strategy followed for the synthesis of the pyr-
rolizidine alkaloids is outlined in Scheme 3. We took advan-
tage of a stereocontrolled cyclic nitrone cycloaddition strat-
egy[15] employing polyfunctionalized nitrone 12 and suitable
dipolarophiles 13, which afforded regio- and stereoselec-
tively isoxazolidines 14. These were then converted into pyr-
rolizidinone derivatives 15 by reductive ring-opening/cycli-
zation. Intermediates 15 bear a free hydroxy group at C6 of
the pyrrolizidine ring, which allows selective glucosylation
at this position. A good choice of dipolarophile is crucial
for the success of the strategy. For instance, for the synthesis
of casuarine (1) a good regioselectivity of the cycloaddition
was assured by using dipolarophile 13 with Y = SiMe2Ph
and X = OEt.[11]
Scheme 3. General procedure for the synthesis of the pyrrolizidine
alkaloids.
Nitrone 12 was conveniently prepared on a multigram
scale by starting from commercially available tribenzyl -
arabinose.[16] It has the absolute configuration of the ste-
reogenic centres at C1, C2 and C3 required for casuarine
and its analogues such as non-natural 7-deoxycasuarine
(4),[16a,17] its lactam derivative 6 and hyacinthacine A2
(11).[16a,18]
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The first key step in the synthesis of 7-deoxycasuarine
(4), its lactam derivative 6 and hyacinthacine A2 (11) is the
1,3-dipolar cycloaddition of nitrone 12 to dimethylacrylam-
ide, which, after N–O bond cleavage of the isoxazolidine
14a with Zn in acetic acid gave lactam 16 in 68% yield over
two steps (Scheme 4). Compound 16 is the key intermediate
for the total synthesis of all three target molecules. Hydro-
genation in EtOH catalysed by Pd/C afforded lactam 6 in
88% yield. Reduction of the C=O bond with LiAlH4 in
THF at reflux gave compound 17 in 75% yield, which, after
catalytic hydrogenation in EtOH, afforded 7-deoxycasuar-
ine (4) in 88% yield (Scheme 4). Deoxygenation at C6 was
achieved through the mesylation of 16 followed by re-
duction with LiAlH4 in THF at reflux. This gave 18 in 80%
yield over two steps. Finally, catalytic hydrogenation gave
hyacinthacine A2 (11) in 72% yield (Scheme 4).
Scheme 4. Syntheses of 7-deoxycasuarine (4), its lactam derivative
6 and hyacinthacine A2 (11): Reagents and conditions: (a) dimeth-
ylacrylamide, CH2Cl2, room temp., 3 d, 85%; (b) Zn, AcOH/H2O,
50 °C, 4 h, 80%; (c) H2, Pd/C, EtOH, 3 d, 88%; (d) LiAlH4, THF,
reflux, 3 h, 75%; (e) H2, Pd/C, HCl, EtOH, 3 d, 88%; (f) MsCl,
NEt3, CH2Cl2, room temp., 2 h, 100%; (g) LiAlH4, THF, reflux,
1.5 h, 80%; (h) H2, Pd/C, HCl, MeOH, 3 d, 72%.
The lactam intermediate 16 was also employed in the
synthesis of glucoside 5; the initial selective α-glucosylation
provided compound 19.[19] Reduction of its amide moiety
with LiAlH4 followed by catalytic hydrogenolysis gave 5 in
45% yield over two steps (Scheme 5).
Scheme 5. Synthesis of 7-deoxycasuarine glucosyl derivative 5: Rea-
gents and conditions: (a) 2,3,4,6-tetra-O-benzylglucopyranosyl tri-
chloroacetimidate, TMSOTf, Et2O, 1 h, 88%; (b) LiAlH4, THF,
room temp., 1 h, 58%; (c) H2, Pd/C, HCl, MeOH, room temp.,
18 h, 77%.
For the synthesis of the non-natural 7-homocasuarine (7)
and of its glucosyl derivatives 8–10, dimethyl maleate was
chosen as the dipolarophile. Treatment of the isoxazolidine
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14b with Zn in acetic acid at 50 °C for 3 h gave lactam 20
in 70% yield over two steps (Scheme 6). Reduction of both
the ester and lactam moieties with excess LiAlH4 in THF
at reflux provided diol 21 quantitatively. Finally, catalytic
hydrogenolysis with Pd/C as catalyst in the presence of HCl
gave non-natural 7-homocasuarine (7) in 89% yield
(Scheme 6).
Scheme 6. Synthesis of 7-homocasuarine (7). Reagents and condi-
tions: (a) dimethyl maleate, CH2Cl2, room temp., 4 d, 78%; (b) Zn,
AcOH/H2O, 50 °C, 3 h, 90%; (c) LiAlH4, THF, reflux, 2 h, 100%;
(d) H2, Pd/C, HCl, EtOH, room temp., 4 d, 89%.
Lactam 20 was also selectively α-glucosylated to give α-
glucoside 22 in 75% yield.[19] Intermediate 22 could be ma-
nipulated in different ways allowing us to obtain the three
glucosyl derivatives 8–10. Catalytic hydrogenolysis of 22 af-
forded compound 10 (96%), which retained both the ester
and lactam moieties. Treatment of 22 with excess LiBH4
and BH3·THF[20] led to the complete reduction of both the
ester and lactam moieties, and subsequent catalytic hydro-
genolysis afforded the target glucosylated 7-homocasuarine
8 in 77% yield over two steps. Selective reduction of the
ester moiety was achieved by treatment of 22 with LiBH4
in THF at room temperature for 18 h. This afforded 23 in
62% yield. Finally, catalytic hydrogenolysis of 23 provided
glucoside 9 in 72% yield (Scheme 7).
Scheme 7. Synthesis of 7-homocasuarine glucosyl derivatives 8–10.
Reagents and conditions: (a) H2, Pd/C, MeOH/EtOAc, room
temp., 4 d, 96%; (b) LiBH4, BH3·THF, THF, room temp., 11 d,
98%; (c) H2, Pd/C, HCl, MeOH, room temp., 12 h, 79%; (d) LiBH4,
THF, room temp., 18 h, 62%; (e) H2, Pd/C, MeOH, 24 h, 72%.
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We recently presented the total synthesis of casuarine (1)
and its 6-O-α-glucoside 2,[11,21] as well as its epimer at C6,
namely uniflorine A,[22] obtained from a derivative of lac-
tam 15 (Y = SiMe2Ph) by inversion of the configuration at
C6. We have now also synthesized the lactam derivative 3
in 77% yield by hydrogenolysis of the fully protected lactam
24 (Scheme 8).[11]
Scheme 8. Synthesis of casuarine 6-O-α-glucoside derivative 3. Rea-
gents and conditions: (a) H2, Pd/C, MeOH/EtOAc, room temp.,
24 h, 77%.
The lactams 10, 9 and 3 were synthesized to investigate
the importance of the basic nitrogen atom in glycosidase
inhibition. With all these compounds in hand, we investi-
gated their inhibitory activity towards a wide range of com-
mercially available glycosidases.
Glycosidase Inhibitory Activities
Compounds 1–11 were assayed with respect to a panel
of 13 commercially available glycosidases (Table 2): α--
fucosidase (EC 3.2.1.51) from bovine kidney, α-galactosid-
ase (EC 3.2.1.22) from coffee beans, β-galactosidase (EC
3.2.1.23) from Escherichia coli and Aspergillus orizae, α-glu-
cosidase (EC 3.2.1.20) from yeast and rice, amyloglucosid-
ase (EC 3.2.1.3) from Aspergillus niger, β-glucosidase (EC
3.2.1.21) from almonds, α-mannosidase (EC 3.2.1.24) from
jack beans, β-mannosidase (EC 3.2.1.25) from snails, β-xy-
losidase (EC 3.2.1.37) from Aspergillus niger, β-N-acetylglu-
cosaminidase (EC 3.2.1.30) from jack beans and bovine
kidney with appropriate p-nitrophenyl glycoside sub-
strates.[23] The errors in the measurements were estimated
to be around 20% (statistical study carried out with model
compounds) and in the concentrations to be around 10–
15% (errors in sample weight). Casuarine (1) was found to
be a potent and competitive inhibitor of amyloglucosidase
from Aspergillus niger (IC50 = 1.90.4 µ, Ki =
2.00.4 µ; ref.[24] IC50 = 0.7 µ). It also inhibits α-gluco-
sidase from yeast and rice (91 and 94% at 1 m, respec-
tively) and, to a lesser extent, β-glucosidase from almonds,
α-mannosidase from jack beans, β-xylosidase from Asper-
gillus niger and β-N-acetylglucosaminidase from jack beans
(46, 21, 24 and 16% at 1 m, respectively). Glucoside 2 was
slightly less potent with the IC50 and Ki values in the same
order of magnitude (IC50 = 4.40.9 µ, Ki = 3.90.8 µ,
mixed-type inhibition; ref.[24] IC50 = 1.1 µ), but more se-
lective than casuarine: indeed at 1 m concentration it gave
only 20% inhibition towards α-glucosidase from yeast and
did not inhibit at all α-glucosidase from rice. Moreover, it
showed only 19% inhibition towards α--fucosidase from
bovine kidney (1 m). Glucosides 5 and 8 and 7-homocasu-
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arine (7) were good and selective competitive inhibitors of
amyloglucosidase from Aspergillus niger (IC50 = 7.71.5,
8.11.6 and 244.7 µ and Ki = 7.41.2, 112.1 and
234.6 µ, respectively). They inhibited α-glucosidase
from yeast weakly (29, 45 and 55% at 1 m, respectively)
and did not inhibit α-glucosidase from rice. 7-Deoxycasuar-
ine (4) was a very potent and selective competitive inhibitor
of amyloglucosidase from Aspergillus niger (IC50 =
4.50.9 µ, Ki = 3.50.7 µ). Among the other glycosid-
ases assayed, only α-glucosidase from rice was also in-
hibited weakly (36% at 1 m). Lactam 6 exhibited weak
(IC50 = 0.210.04 m) but very selective inhibitory ac-
Table 2. Inhibitory activity of compounds 1–11 towards commercially available glycosidases.[a]
Enzyme (pH) 1 2 3 4 5 6
α--Fucosidase n.i. 19 n.i. n.i. n.t. n.i.
Bovine kidney (6)
α-Galactosidase n.i. n.i. n.i. n.i. n.t. n.i.
Coffee beans (6)
β-Galactosidase Escherichia coli (7) n.i. n.i. n.i. n.i. n.t. n.i.
Aspergillus orizae (4) n.i. n.i. n.i. n.i. n.t. n.i.
α-Glucosidase 91 20 n.i. n.i. 29 n.i.
Yeast (7)
Rice (4) 94 n.i. n.i. 36 n.i. n.i.
Amyloglucosidase Aspergillus niger (5) 98 97 n.i. 100 97 91
IC50 = 1.9 µ IC50 = 4.4  IC50 = 4.5 µ IC50 = 7.7 µ IC50 = 0.21 m
Ki = 2.0 µ Ki = 3.9 µ Ki = 3.5 µ Ki = 7.4 µ
β-Glucosidase 46 n.i. n.i. n.i. n.t. 42
Almonds (5)
α-Mannosidase 21 n.i. n.t. n.i. n.t. n.i.
Jack beans (5)
β-Mannosidase n.i. n.t. n.t. n.i. n.t. n.i.
Snails (4)
β-Xylosidase 24 n.t. n.t. n.i. n.t. n.i.
Aspergillus niger (5)
β-N-Acetylglucosaminidase 16 n.t. n.i. n.i. n.t. 44
Jack beans (5)
Bovine kidney (4) n.i. n.t. n.i. n.t. n.t. 20
Enzyme (pH) 7 8 9 10 11
α--Fucosidase n.i. n.t. n.i. n.i. n.t.
Bovine kidney (6)
α-Galactosidase n.i. n.t. n.i. n.i. n.i.
Coffee beans (6)
β-Galactosidase Escherichia coli (7) n.i. n.t. n.i. n.i. n.i.
Aspergillus orizae (4) n.i. n.t. n.i. n.i. n.i.
α-Glucosidase 45 55 n.i. n.i. 72
Yeast (7)
Rice (4) n.i. n.i. n.i. n.i. n.i.
Amyloglucosidase Aspergillus niger (5) 99 92 25 76 97
IC50 = 8.1 µ IC50 = 24 µ IC50 = 1.9 µ
Ki = 11 µ Ki = 23 µ Ki = 2.6 µ
β-Glucosidase n.t. n.t. n.i. n.i. n.i.
Almonds (5)
α-Mannosidase n.t. n.t. n.i. n.i. n.i.
Jack beans (5)
β-Mannosidase n.t. n.t. n.t. n.i. n.i.
Snails (4)
β-Xylosidase n.t. n.t. n.t. n.i. n.i.
Aspergillus niger (5)
β-N-Acetylglucosaminidase n.t. n.t. n.t. n.i. n.i.
Jack beans (5)
Bovine kidney (4) n.t. n.t. n.t. n.i. n.i.
[a] Percentage inhibition at a concentration of 1 m. n.i. = no inhibition, n.t. = test not performed.
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tivity towards amyloglucosidase from Aspergillus niger.
Hyacinthacine A2 (6,7-dideoxycasuarine, 11) was also a
very strong inhibitor of this enzyme (IC50 =
1.9 µ0.4 µ, Ki = 2.6 µ0.5 µ, non-competitive in-
hibition; ref.[25] IC50 = 8.6 µ). Among the remaining com-
pounds, 3 was not active towards any of the glycosidases
assayed, 9 and 10 showed weak and very selective inhibitory
activity (25 and 76% inhibition at 1 m, respectively)
towards amyloglucosidase from Aspergillus niger. Gluco-
sides 5 and 8 together with the parent compound 2 have
also been found to be potent inhibitors of bacterial and
insect trehalases.[19]
Casuarine Analogues
As 2 is a glucoside we verified whether the amyloglucosi-
dase was able to hydrolyse its glucosidic bond or not under
our test conditions. Indeed, we had to consider the possibil-
ity that the inhibitory activities observed for 2 were due to
the casuarine liberated by the hydrolysis reaction catalysed
by amyloglucosidase. Thus, we performed a series of mass
spectral analyses using HR-ESI-TOF-MS (high-resolution
ESI mass spectrometry, positive ionization mode). As
shown in Figure S48 (see the Supporting Information) the
peak assigned to the glucoside (A), MW = 367.35, was de-
tected in solution when the measurement was performed
immediately after the addition of the enzyme (C) as well as
after 20 min of incubation at room temperature (D) and
after 20 min of incubation at 37 °C (E). We verified that the
mixture of enzyme and buffer did not give similar signals
(B). The spectra of the different assays performed with the
buffered solution (phosphate) of the inhibitor in the pres-
ence of the enzyme neither showed peaks corresponding to
the aglycon (MW = 205.21) nor to glucose (180.16) alone
(see Figure S48 of the Supporting Information). This indi-
cates that glucoside 2 is not hydrolysed significantly by the
enzyme (amyloglucosidase from Aspergillus niger) under the
conditions of our test.
Computational Studies
The data reported in Table 2 show that the casuarine de-
rivatives presented here, with the exception of glycosylated
lactams 3, 9 and 10, all inhibit more than 90% of Aspergil-
lus niger amyloglucosidase activity with IC50 values ranging
from 1.9 µ for pyrrolizidines 1 and 11 to 24 µ for gluco-
side 8, with lactam 6 showing the weakest activity
(0.21 m). Furthermore, the active compounds showed a
competitive inhibition profile, thus indicating a similar
binding mode within the enzyme. Nevertheless, no signifi-
cant differences were found in the inhibition activity of glu-
cosides and their parent compounds, which clearly indicates
a lack of correlation between inhibition and the ability to
occupy a second subsite.
In the past years, several crystallographic structures of
the proteolytic fragment of glucoamylase G2 from Aspergil-
lus awamori (95% sequence identity with the A. niger pro-
tein) bound to different inhibitors have been reported,[26]
which has made it possible to investigate the nature of the
interaction between glucoamylase and its ligands in detail.
The enzyme active site is characterized by an excess of
negative charge, which has been principally ascribed to resi-
dues D55, E179 and E400 from the –1 subsite. Further-
more, E179 and E400 have been shown to be the putative
catalytic acid and base, respectively, and the hydrolysis reac-
tion was hypothesized to proceed through the formation of
a glucopyranosyl cation intermediate after nucleophilic at-
tack by a water molecule. With this information in mind
and with the aim to interpret the biological data in a struc-
tural way, we decided to study the docking on the glu-
coamylase structure to investigate the possible binding
mode of the casuarine derivatives presented here.
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After completion of docking calculations, ring A of casu-
arine (1) was found to be deeply located within the –1 site
where it is involved in an optimal hydrogen-bonding net-
work involving C8–OH and C2–OH of the ligand and
active-site residues R54 and D55 together with the nucleo-
philic water Wat501. In addition, C1–OH is positioned at a
hydrogen-bond distance from both the carbonyl oxygen
atom of residue L177 and Wat501 (Figure 1). All other pyr-
rolizidine molecules were oriented in a similar way and con-
served these interactions, which have also been observed in
the crystallographic complexes with both DNJ and acar-
bose.[26a,26b]
Figure 1. Docked orientation of molecule 1 within the glucoamyl-
ase active site. Hydrogen-bonds are depicted as magenta dashed
lines.
As a consequence of this orientation, the protonated ni-
trogen atom of pyrrolizidine derivatives is not involved in
the strong hydrogen-bond interaction with E179 observed
for the nitrogen atom in the acarbose complex,[26b] but is
oriented towards the region in which the nucleophile
Wat501 lies, analogous to what was observed for the imi-
nosugar-type inhibitor DNJ.[26a] We could hypothesize that
the high affinity of acarbose (Ki = 10–12 )[26b] for glu-
coamylase is due, at least in part, to the presence of the
charged hydrogen-bond interaction with E179 given that it
has been suggested that charged hydrogen bonds can be re-
sponsible for a change in the binding constant by a factor
of 1000.[27] Indeed, a maltoside hetero-analogue carrying a
nitrogen atom at the interglycosidic linkage, which enables
it to establish a charged hydrogen bond with E179, showed
a 1000-fold stronger competitive inhibition than the ana-
logue in which the interglycosidic atom is sulfur.[28] In con-
trast, a comparison of the crystal complexes of GA with
acarbose and its weaker -gluco-dihydro derivative (Ki =
10–8 ) shows that the two molecules bind in a very similar
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way (including the charged hydrogen bond with E179), and
the 6 kcal/mol difference in binding energies could be
largely attributed to unfavourable steric interactions be-
tween the hydrogen atoms at C7A of -gluco-dihydroacar-
bose and the catalytic water,[26b] thus highlighting a com-
parable effect of electrostatic and hydrophobic interactions
in guiding interactions with GA. Molecules 1, 4, 6 and 7
are able to bind E179 through a neutral hydrogen bond in-
volving C6–OH, whereas the 6-deoxy derivative 11 clearly
lacks this interaction. Anyway, apart from C6–OH when
present, pyrrolizidine ligands are oriented towards the nega-
tively charged E179, a very hydrophobic portion of the mo-
lecule, which could contribute negatively to the binding.
With respect to the crystallographic orientation of acar-
bose, the ring B atoms of the pyrrolizidines extend towards
the +1 site, with C6 and C7 of 1 almost perfectly overlapped
with C5B and N4B of the acarbose ring B, respectively. C7–
OH of 1 is thus in close proximity to both R305 and the
carbonyl oxygen atom of W178, but it does not present the
correct geometry for hydrogen-bond formation, in contrast
to what has been observed for C3B–OH of acarbose. The
elimination of the C7 substituent (molecule 4) led to a slight
decrease in the IC50 value as well as its elongation (molecule
7), although this latter modification allowed the molecule
to hydrogen-bond to both W178 and R305. Molecule 6,
which shows a very weak inhibition, is the only non-glycos-
ylated lactam of this series, and after docking it is oriented
like molecule 4. Anyway, given the limited conformational
flexibility imposed on molecule 6 by the presence of the
lactam structure, the conformation of ring B is clearly influ-
enced. Indeed, molecule 6 is also able to hydrogen-bond
E179 through C6–OH, but the absence of the positive
charge on the nitrogen atom eliminates the possibility of
molecule 6 compensating the excess negative charge present
in the glucoamylase active site, which has been hypothe-
sized as one of the mechanisms involved in complex stabili-
sation.[26a,26b] Finally, the unfavourable effects due to the
positioning of a hydrophobic portion of the ligand close to
a charged amino acid (E179) is even more pronounced here
given the higher hydrophobicity of 6 relative to 4. All these
considerations are in agreement with the very low IC50
value found for 6.
As far as the glucoside derivatives are concerned, the re-
sults of the docking calculations are comparable for all mo-
lecules, with ligands showing two possible binding modes
in which either the pyrrolizidine or the glucose moiety is
oriented in the –1 site; we call these two orientations CAS-
IN and GLU-IN, respectively. In the CAS-IN orientation,
the position of the pyrrolizidine nucleus is almost coinci-
dent with the docked pose of the corresponding unglucosyl-
ated compounds, except for the conformation of ring B,
which is influenced by the positioning of the glucose moi-
ety, and for the lack of a hydrogen-bond donor for E179 at
the C6 atom. The glucose moiety is oriented in the outer
part of the +1 site, where it can assume different conforma-
tions that allow it to hydrogen-bond E180 and/or Y311.
When the molecules adopt the GLU-IN orientation, the
glucose in the –1 site overlaps well with DNJ and with
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ring A of acarbose. In all the selected poses showing this
orientation the pyrrolizidine nucleus orients the N–H+
towards the aromatic ring of Y311 in the +1 site with a
geometry compatible with an NH· π interaction. Further-
more, C8–OH is able to donate one hydrogen bond to E180,
thus contributing to the stabilization of this binding mode.
Anyway, by comparison of the GLU-IN orientation of 2
with the docked orientation of the hydrolysable maltose,
which perfectly overlaps the glucose moiety of 2 with its
non-reducing end, it is not clear how the casuarine gluco-
side could resist hydrolysis, as we observed, because the nu-
cleophile Wat501 is perfectly oriented towards the anomeric
carbon atom of the ligand. In contrast, the CAS-IN binding
mode of glucosides explains the resistance to hydrolysis that
we observed for molecule 2 because the glucose moiety is
located in the +1 site, far from the nucleophile Wat501.
Moreover, given the longer C2–C6 distance of pyrrolizidine
(4.9 Å) with respect to the C1–C4 distance of glucose
(2.9 Å), the CAS-IN orientation allows ring B of pyrrolizid-
ine to extend to the +1 site such that the glucose moiety is
projected towards the third GA subsite (see Figure S49 of
the Supporting Information). Interestingly, after docking,
the lactam derivatives of glucosides 3, 9 and 10, which did
not show inhibitory activity, all adopted the same GLU-IN
orientation. The interactions of glucose at the –1 site are
the same as those observed for active glucosides, and at the
level of the +1 site the results of docking converged to a
unique solution, which differ from the active glucosides for
the aglycon conformation clearly influenced by the pres-
ence/absence of the lactam structure. Furthermore, the ab-
sence of charge on the nitrogen atom prevents lactam deriv-
atives in the GLU-IN orientation from reinforcing the inter-
action at the +1 site through NH· π interactions. These ob-
servations on lactam molecules highlight some interesting
features of the GA interaction: the fact that the CAS-IN
orientation was never found for lactam-glucoside, together
with the observations we made on the structural features of
the interaction with molecule 6, clearly indicate a poor
binding of the lactam moiety to the –1 site due to both the
absence of positive charge on the ligand and the steric ef-
fects associated with the lactam structure. Given also that
at the +1 site the lack of charge on the ligand could be
detrimental to the binding affinity and considering that the
GLU-IN orientation of glucoside molecules could be asso-
ciated with the hydrolysis of the molecule, it is not surpris-
ing that lactam molecules are not able to inhibit glucoamyl-
ase.
In summary, we have analysed the binding features of
competitive pyrrolizidine inhibitors of glucoamylase as de-
termined by docking simulations. None of the molecules we
considered in this study presented structural variations in
ring A, which in casuarine perfectly mimics the stereochem-
ical arrangement of glucose. As far as ring B is concerned,
none of the structural variations introduced at the 6- (in-
cluding glycosylation) and 7-positions seem to significantly
influence the inhibitory activity. In contrast, the presence
of the lactam structure at the 4- and 5-positions has a very
dramatic effect on the activity, and this could be due to
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both the lack of a positive charge, whose role in stabilizing
the complex has been already highlighted, and the limited
conformational flexibility, which could determine unfavour-
able steric contacts.
Conclusions
We have reported a novel and efficient strategy for the
synthesis of casuarine-like pyrrolizidines and their 6-O-α-
glucoside derivatives. Our methodology was based on a tot-
ally regio- and stereoselective 1,3-dipolar cycloaddition of
suitably substituted alkenes with a carbohydrate-based
nitrone. After N–O bond cleavage of the cycloadducts thus
obtained, the lactams were used as key intermediates in the
synthesis of all the target compounds, including the gluco-
syl derivatives that were obtained by selective α-glucosyl-
ation. Evaluation of the inhibitory activity of casuarine and
its derivatives towards a wide range of commercially avail-
able glycosidases was undertaken, and several new inhibi-
tors of glucoamylase from Aspergillus niger were discov-
ered. Docking experiments performed on pyrrolizidine de-
rivatives allowed us to investigate the binding mode of the
competitive inhibitors. It is evident that an optimal network
of hydrogen-bonding interactions at the inner –1 site has to
be achieved for a ligand to bind. The presence of a positive
charge on the ligand is helpful for the stabilization of the
complex, independently of the possibility that a ligand has
to hydrogen-bond E179 through the charged atom. Finally,
interactions at the +1 site also seem to have an important
role in modulating the affinity of more extended molecules,
but the comparison of 2 with acarbose clearly shows that
to increase the affinity for GA it is necessary to bind sub-
sites outside of the +1 site.
Experimental Section
General: Commercial reagents were used as received. All reactions
were carried with magnetic stirring and were monitored by TLC
on 0.25 mm silica gel plates (Merck F254). Column chromatography
was carried out on silica gel 60 (32–63 mm). Yields refer to spectro-
scopically and analytically pure compounds unless otherwise
stated. 1H NMR spectra were recorded with a Varian Mercury-
400 spectrometer. 13C NMR spectra were recorded with a Varian
Gemini-200 spectrometer. Infrared spectra were recorded with a
Perkin–Elmer Spectrum BX FT-IR System spectrophotometer.
Mass spectra were recorded with a QMD 1000 Carlo Erba instru-
ment by direct inlet injection; relative percentages are shown in
parentheses. ESI full mass spectra were recorded with a Thermo
LTQ instrument by direct inlet injection; relative percentages are
shown in parentheses. HR-ESI-TOF-MS experiments were per-
formed with a Q-Tof Ultima mass spectrometer (Waters) fitted with
a standard Z-spray ion source and operated in the positive ioniza-
tion mode. Elemental analyses were performed with a Perkin–El-
mer 2400 analyser. Optical rotation measurements were performed
with a JASCO DIP-370 polarimeter.
(1R,2R,3R,6R,7aR)-1,2-Bis(benzyloxy)-3-[(benzyloxy)methyl]-6-hy-
droxyhexahydro-5H-pyrrolizin-5-one (16): A mixture of 14a
(816 mg, 1.58 mmol) and Zn dust (407 mg) in CH3COOH/H2O
(9:1, 12.5 mL) was heated at 50 °C for 4 h and then filtered through
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cotton. The solution was cooled to 0 °C, and, under vigorous stir-
ring, a saturated aqueous solution of NaHCO3 (100 mL) was added
until a basic pH was reached. The aqueous phase was extracted
with EtOAc (320 mL), and the combined organic phases were
dried with Na2SO4. After filtration and concentration under re-
duced pressure, 16 was obtained as a yellow oil, pure enough to be
used in the next step (598 mg, 80%). An analytically pure sample
was obtained through purification by flash column chromatog-
raphy on silica gel (eluent: petroleum ether/EtOAc, 1:2, Rf = 0.4).
[α]D20 = +3.05 (c = 0.9, CHCl3). 1H NMR (400 MHz, CDCl3): δ =
7.38–7.26 (m, 15 H, Ar), 4.60–4.45 (m, 7 H, Bn, 6-H), 4.34 (t, J =
4.3 Hz, 1 H, 2-H), 4.11 (q, J = 4.5 Hz, 1 H, 3-H), 3.87 (br. s, 1 H,
OH), 3.79 (dd, J = 6.9, 5.0 Hz 1 H, 1-H), 3.73 (dt, J = 8.6, 6.5 Hz,
1 H, 7a-H), 3.63 (dd, J = 9.8, 5.5 Hz, 1 H, 8-Ha), 3.52 (dd, J =
9.8, 4.1 Hz, 1 H, 8-Hb), 2.70 (ddd, J = 12.3, 7.8, 6.1 Hz, 1 H, 7-
Ha), 1.80 (ddd, J = 12.3, 10.4, 8.6 Hz, 1 H, 7-Hb) ppm. 13C NMR
(50 MHz, CDCl3): δ = 174.5 (s, C=O), 137.8, 137.7, 137.4 (s, Ar),
128.5–127.6 (d, 15 C, Ar), 89.1 (d, C-1), 85.7 (d, C-2), 73.3, 72.6,
72.4 (t, Bn), 72.0 (d, C-6), 68.8 (t, C-8), 59.9 (d, C-7a), 58.6 (d, C-
3), 37.2 (t, C-7) ppm. IR (CDCl3): ν˜ = 3671, 3373, 3012, 2867,
1697, 1454, 1100 cm–1. MS (EI): m/z (%) = 381 (12) [M – Bn]+, 336
(20), 275 (32), 180 (98), 153 (100), 88 (100). C29H31NO5 (473.56):
calcd. C 73.55, H 6.60, N 2.96; found C 73.33, H 6.80, N 2.87.
(1R,2R,3R,6R,7aR)-1,2,6-Trihydroxy-3-(hydroxymethyl)hexahydro-
5H-pyrrolizin-5-one (6): Pd (10% on C, 300 mg) was added to a
stirred solution of 16 (150 mg, 0.32 mmol) in EtOH (15 mL) under
nitrogen. The suspension was stirred under hydrogen at room temp.
for 3 d, then filtered through Celite® and washed with MeOH.
Concentration under reduced pressure afforded a viscous oil that
was purified by flash column chromatography on silica gel (eluent:
MeOH/EtOAc, 1:3, Rf = 0.14) to afford pure 6 as a transparent oil
(57 mg, 88% yield). [α]D20 = –1.2 (c = 0.25, MeOH). 1H NMR
(400 MHz, CD3OD): δ = 4.54 (dd, J = 10.5, 7.8 Hz, 1 H, 6-H),
4.16 (t, J = 6.3 Hz, 1 H, 2-H), 3.84 (dd, J = 3.0, 8.0 Hz, 1 H, 8-
Ha), 3.67–3.53 (m, 4 H, 8-Hb, 1-H, 3-H, 7a-H), 2.78 (ddd, J =
12.2, 7.8, 5.9 Hz, 1 H, 7-Ha), 1.74 (ddd, J = 12.0, 10.7, 8.3 Hz, 1
H, 7-Hb) ppm. 13C NMR (50 MHz, CD3OD): δ = 175.3 (s, C-5),
81.8 (d, C-1), 78.3 (d, C-2), 71.7 (d, C-6), 62.0 (d, C-3), 60.2 (t, C-
8), 59.8 (d, C-7a), 36.8 (t, C-7) ppm. MS: m/z (%) = 204 (5) [M +
H]+, 203 (3) [M]+, 185 (27) [M – H2O]+, 172 (52), 144 (74), 126
(51), 100 (87), 86 (100), 72 (59), 57 (38). C8H13NO5 (203.19): calcd.
C 47.29, H 6.45, N 6.89; found C 47.54, H 6.36, N 6.95.
(1R,2R,3R,6R,7aR)-1,2-Bis(benzyloxy)-3-[(benzyloxy)methyl]hexa-
hydro-1H-pyrrolizin-6-ol (17): A 1  solution of LiAlH4 in THF
(1.6 mL, 1.61 mmol) was added to a cooled (0 °C) solution of 16
(255 mg, 0.54 mmol) in dry THF (6 mL) under nitrogen. The mix-
ture was then heated at reflux for 1.5 h. Then, after cooling to
0 °C, an aqueous saturated solution of Na2SO4 (560 µL) was added
dropwise. The suspension was then filtered through Celite® and
washed with EtOAc. Concentration under reduced pressure af-
forded 17 as a yellow oil pure enough for the next step (185 mg,
75% yield). An analytically pure sample was obtained through pu-
rification by flash column chromatography on silica gel (eluent:
petroleum ether/EtOAc, 1:4, Rf = 0.3). [α]D20 = +9.1 (c = 0.83,
CHCl3). 1H NMR (400 MHz, CDCl3): δ = 7.36-7.24 (m, 15 H, Ar),
4.67–4.46 (m, 6 H, Bn), 4.35–4.31 (m, 1 H, 6-H), 4.11 (t, J = 4.6 Hz,
1 H, 1-H), 4.07 (t, J = 4.7 Hz, 1 H, 2-H), 3.60-3.44 (m, 4 H, 7a-H,
3-H, 8-Ha, 8-Hb), 3.21 (dd, J = 12.3, 4.5 Hz 1 H, 5-Ha), 2.98 (dm,
J = 12.3 Hz, 1 H, 5-Hb), 2.21 (ddd, J = 13.8, 9.0, 5.7 Hz, 1 H, 7-
Ha), 1.84 (dm, J = 13.8 Hz, 1 H, 7-Hb) ppm. 13C NMR (50 MHz,
CDCl3): δ = 138.1, 137.8, 137.4 (s, Ar), 128.1-127.2 (d, 15 C, Ar),
88.9 (d, C-1), 85.2 (d, C-2), 73.6 (d, C-6), 72.9, 72.1, 71.8, 71.6 (t,
Bn, C-8), 69.9 (d, C-3), 67.4 (d, C-7a), 63.3 (t, C-5), 40.0 (t, C-7)
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ppm. IR (CDCl3): ν˜ = 3392, 3010, 2927, 2858, 1748, 1710, 1454,
1262 cm–1. MS (EI): m/z (%) = 366 (6), 336 (6), 216 (61), 160 (100),
90 (100). C29H33NO4 (459.58): calcd. C 75.79, H 7.24, N 3.05;
found C 75.99, H 7.16, N 3.02.
(1R,2R,3R,6R,7aR)-3-(Hydroxymethyl)hexahydro-1H-pyrrolizine-
1,2,6-triol (7-Deoxycasuarine, 4): Concentrated HCl (4–5 drops)
and Pd (10% on C, 250 mg) were added to a stirred solution of
17 (120 mg, 0.26 mmol) in EtOH (10.5 mL) under nitrogen. The
suspension was stirred at room temp. under hydrogen for 3 d, then
filtered through Celite® and washed with MeOH. Concentration
under reduced pressure afforded a viscous yellow oil (66 mg) that
was transferred to a column of DOWEX 50WX8 and then washed
with MeOH (10 mL), H2O (10 mL) to remove non-amine-contain-
ing products and then with 6% NH4OH (15 mL) to elute 7-deoxy-
casuarine (4) as a white solid (43 mg, 88% yield), m.p. 205–208 °C.
[α]D20 = +19.8 (c = 0.4, H2O) {ref.[17a] [α]D20 = +10.9 (c = 0.11, H2O);
ref.[16b] [α]D25 = +23 (c = 0.3, MeOH)}. 1H NMR (400 MHz, D2O):
δ = 4.44–4.38 (m, 1 H, 6-H), 4.05 (t, J = 8.2 Hz, 1 H, 1-H), 3.74–
3.69 (m, 2 H), 3.56 (dd, J = 11.9, 6.5 Hz, 1 H), 3.24 (ddd, J = 12.6,
8.2, 4.2 Hz, 1 H), 3.09–3.02 (m, 2 H), 2.86 (m, 1 H, 5-Hb), 2.12
(ddd, J = 13.6, 8.5, 3.4 Hz, 1 H, 7-Ha), 1.89 (dm, J = 13.6 Hz, 1
H, 7-Hb) ppm. 13C NMR (50 MHz, D2O): δ = 82.6 (d, C-1), 79.0
(d, C-2), 75.1 (d, C-6), 72.5 (d, C-7a), 67.9 (d, C-3), 64.6 (t, C-8),
63.3 (t, C-5), 39.3 (t, C-7) ppm. MS (EI): m/z (%) = 190 (3) [M +
H]+, 189 (1) [M]+, 176 (66), 158 (65) [M – CH2OH]+, 132 (64), 112
(23), 85 (62), 58 (100). C8H15NO4 (189.21): calcd. C 50.78, H 7.99,
N 7.40; found C 50.37, H 7.63, N 7.74.
(1R,2R,3R,7aR)-1,2-Bis(benzyloxy)-3-(benzyloxymethyl)hexahydro-
1H-pyrrolizine (18): NEt3 (75 µL, 0.54 mmol) was added to a
stirred solution of 16 (95 mg, 0.20 mmol) in dry CH2Cl2 (0.45 mL)
under nitrogen, and, at 0 °C, MsCl (20 µL, 0.26 mmol) was added
dropwise. The solution was stirred at 0 °C for 30 min and at room
temp. for 2 h. The mixture was filtered through Celite® and washed
with EtOAc. Concentration under reduced pressure afforded the
mesylated derivative as a white oil (quantitative yield), which was
dissolved in dry THF (2.5 mL). A 1  solution of LiAlH4 in THF
(0.8 mL, 0.8 mmol) was added dropwise at 0 °C under nitrogen.
The mixture was heated at reflux for 3 h. An aqueous saturated
solution of Na2SO4 (280 µL) was added dropwise, and the mixture
was stirred at room temp. for 10 min. After filtration through Ce-
lite®, a crude residue (109 mg) was obtained that was purified by
flash column chromatography on silica gel (petroleum ether/ethyl
acetate, 1:2, Rf = 0.28) to afford pure 18 (71 mg, 80% yield) as an
oil. [α]D24 = –5.1 (c = 0.6, CHCl3). 1H NMR (400 MHz, CDCl3): δ
= 7.37–7.25 (m, 15 H, Ar), 4.73–4.46 (m, 6 H, Bn), 4.08 (dd, J =
7.4, 5.9 Hz, 1 H, 2-H), 3.81 (t, J = 5.9 Hz, 1 H, 1-H), 3.60 (dd, J
= 9.6, 4.7 Hz, 1 H, 8-Ha), 3.54 (dd, J = 9.6, 5.7 Hz, 1 H, 7a-H),
3.51–3.46 (m, 1 H, 8-Hb), 3.07 (dt, J = 10.5, 6.1 Hz, 1 H, 5-Ha),
2.98–2.94 (m, 1 H, 3-H), 2.78 (dt, J = 10.5, 6.6 Hz, 1 H, 5-Hb),
2.03–1.95 (m, 1 H, 7-Ha), 1.91–1.82 (m, 1 H, 6-Ha), 1.81–1.74 (m,
1 H, 6-Hb), 1.72–1.62 (m, 1 H, 7-Hb) ppm. 13C NMR (50 MHz,
CDCl3): δ = 138.2, 138.1, 137.9 (s, Ar), 128.0–127.1 (d, 15 C, Ar),
88.6 (d, C-1), 85.5 (d, C-2), 73.0, 72.3, 71.8, 71.6 (t, C-8, Bn), 68.0
(d, C-3), 67.2 (d, C-7a), 54.8 (t, C-5), 31.4 (t, C-6), 25.5 (t, C-7)
ppm.
(1R,2R,3R,7aR)-3-(Hydroxymethyl)hexahydro-1H-pyrrolizine-1,2-
diol (Hyacinthacine A2, 11): Concentrated HCl (3 drops) and Pd
(10% on C, 45 mg) were added to a stirred solution of 18 (25 mg,
0.056 mmol) in MeOH (2.5 mL). The mixture was stirred at room
temp. under hydrogen for 3 d. The mixture was then filtered
through Celite® and washed with MeOH. The solvent was evapo-
rated under reduced pressure to afford a viscous white oil that was
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transferred to a column of DOWEX 50WX8 and then washed with
MeOH (10 mL), H2O (10 mL) to remove non-amine-containing
products and then with 6% NH4OH (15 mL) to elute hyacinthac-
ine A2 (11) as a white solid (7 mg, 72% yield). [α]D24 = +12.4 (c =
0.2, H2O); {ref.[16a] [α]D24 = +12.7 (c = 0.13, H2O); ref.[18a] [α]D =
+12.5 (c = 0.4, H2O); ref.[16c] [α]D20 = +19.9 (c = 0.97, MeOH);
ref.[18b] [α]D25 = +10.5 (c = 0.6, H2O); ref.[18f] [α]D = +12.1 (c = 0.3,
H2O); ref.[18g] [α]D26 = +12 (c = 0.4, H2O); ref.[25] [α]D = +20.1 (c =
0.44, H2O)}. 1H NMR (200 MHz, D2O): δ = 3.72–3.61 (m, 3 H),
3.53 (dd, J = 11.7, 6.2 Hz, 1 H), 3.10–3.00 (m, 1 H), 2.86–2.75 (m,
1 H), 2.70–2.56 (m, 2 H), 1.90–1.58 (m, 4 H) ppm. 13C NMR
(50 MHz, D2O): δ = 82.6 (d, C-1), 79.6 (d, C-2), 71.7 (d, C-3), 68.6
(d, C-7a), 65.3 (t, C-8), 57.4 (t, C-5), 32.2 (t, C-7), 27.0 (t, C-6)
ppm. C8H15NO3 (173.21): calcd. C 55.47, H 8.73, N 8.09; found C
55.49, H 8.61, N 8.10.
Methyl (1S,2R,6R,7R,7aR)-6,7-Bis(benzyloxy)-5-[(benzyloxy)meth-
yl]-2-hydroxy-3-oxohexahydro-1H-pyrrolizine-1-carboxylate (20): A
mixture of 14b (870 mg, 1.55 mmol) and Zn dust (400 mg,
6.2 mmol) in CH3COOH/H2O (9:1, 12.5 mL) was heated at 50 °C
for 3 h and then filtered through cotton. The solution was cooled
to 0 °C, and, under vigorous stirring, a saturated aqueous solution
of NaHCO3 (100 mL) was added until a basic pH was reached.
The aqueous phase was extracted with EtOAc (360 mL), and the
combined organic phases were dried with Na2SO4. After filtration
and concentration under reduced pressure, 20 was obtained pure
as a white solid (743 mg, 90% yield), m.p. 111–113 °C. [α]D20 = –28.7
(c = 0.64, CHCl3). 1H NMR (400 MHz, CDCl3): δ = 7.37–7.23 (m,
15 H, Ar), 4.76 (dd, J = 9.8, 2.9 Hz, 1 H, 2-H), 4.57–4.44 (m, 6 H,
Bn), 4.31–4.28 (m, 1 H, 5-H), 4.23–4.22 (m, 1 H, 6-H), 3.98–3.95
(m, 1 H, 7a-H), 3.92–3.90 (m, 1 H, 7-H), 3.79 (s, 3 H, Me), 3.58–
3.50 (m, 2 H, 8-H), 3.44 (d, J = 3.1 Hz, 1 H, OH), 3.03 (t, J =
9.3 Hz, 1 H, 1-H) ppm. 13C NMR (50 MHz, CDCl3): δ = 173.2,
171.1 (s, C=O), 137.7–137.2 (s, 3 C, Ar), 128.4–127.5 (d, 15 C, Ar),
87.3 (d, C-7), 84.6 (d, C-6), 74.2 (d, C-2), 73.1, 72.1, 71.8 (t, Bn),
68.1 (t, C-8), 62.7 (d, C-7a), 59.3 (d, C-5), 54.8 (d, C-1), 52.5 (q,
Me) ppm. IR (CHCl3): ν˜ = 3690, 3600–3500 (br), 3027, 2920, 1708,
1601, 1155, 1070 cm–1. MS (EI): m/z (%) = 513 (0.6) [M – H2O]+,
212 (4), 91 (100), 69 (14). C31H33NO7 (531.6): calcd. C 70.04, H
2.63, N 6.26; found C 70.02, H 2.56, N 6.28.
(1R,2R,3R,6R,7R,7aR)-1,2-Bis(benzyloxy)-3-[(benzyloxy)methyl]-7-
(hydroxymethyl)hexahydro-1H-pyrrolizin-6-ol (21): A 1  solution
of LiAlH4 in THF (1.1 mL, 1.1 mmol) was added to a cooled (0 °C)
solution of 20 (115 mg, 0.22 mmol) in dry THF (3 mL) under nitro-
gen. The mixture was then heated at reflux for 2 h. Then, after
cooling at 0 °C, an aqueous saturated solution of Na2SO4 (700 µL)
was added dropwise. The suspension was then filtered through Ce-
lite® and washed with EtOAc. Concentration under reduced pres-
sure afforded solid 21 pure enough to be used in the next step
(104 mg, quantitative yield). An analytically pure sample was ob-
tained by filtration through a short pad of silica gel (eluent: EtOAc
then EtOAc/MeOH, 5:1), m.p. 85–87 °C. [α]D20 = +3.58 (c = 1.18,
CHCl3). 1H NMR (400 MHz, CDCl3): δ = 7.40–7.25 (m, 15 H,
Ar), 4.64–4.56 (m, 6 H, Bn), 4.22 (q, J = 5.6 Hz, 1 H, 6-H), 4.13–
4.09 (m, 2 H, 1-H, 2-H), 3.68 (d, J = 6.8 Hz, 2 H, 8-Ha, 8-Hb),
3.53 (d, J = 6.4 Hz, 2 H, 9-Ha, 9-Hb) 3.43–3.37 (m, 2 H, 3-H, 5-
Ha) 3.27 (dd, J = 7.0, 3.9 Hz, 1 H, 7a-H), 2.95 (dd, J = 10.8,
5.6 Hz, 1 H, 5-Hb), 2.24 (quint., J = 6.6 Hz, 1 H, 7-H) ppm. 13C
NMR (50 MHz, CDCl3): δ = 138.2–137.7 (s, 3 C, Ar), 128.5–127.5
(d, 15 C, Ar), 88.0 (d), 86.1 (d), 76.6 (d), 73.3 (t), 72.4 (t), 72.0 (t),
71.5 (t), 70.4 (d), 70.4 (d), 64.2 (t), 62.4 (t), 54.3 (d) ppm. IR
(CDCl3): ν˜ = 3412, 3031, 3010, 2866, 1496, 1454, 1363, 1216, 1212,
1211, 1097 cm–1. MS (EI): m/z (%) = 398 (11) [M – C7H7]+, 368
(85), 248 (11), 186 (27), 160 (30), 142 (25), 116 (22), 91 (100), 64
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(21). C30H35NO5 (489.6): calcd. C 73.59, H 7.21, N 2.86; found C
73.58, H 7.09, N 3.18.
(1R,2R,3R,6R,7R,7aR)-3,7-Bis(hydroxymethyl)hexahydro-1H-pyr-
rolizine-1,2,6-triol (7-Homocasuarine, 7): Concentrated HCl (4–
5 drops) and Pd (10% on C, 230 mg) were added to a stirred solu-
tion of 21 (106 mg, 0.22 mmol) in EtOH (14 mL). The suspension
was stirred at room temp. under hydrogen for 4 d, then filtered
through Celite® and washed with EtOH. Evaporation under re-
duced pressure afforded a viscous oil that was transferred to a col-
umn of DOWEX 50WX8 and then washed with MeOH (10 mL),
H2O (10 mL) to remove non-amine-containing products and then
with 6% NH4OH (15 mL) to elute 7-homocasuarine (7). Evapora-
tion of the solvent afforded 7-homocasuarine as a yellow viscous
oil (38.5 mg, 89%). [α]D20 = +30.8 (c = 0.7, MeOH). 1H NMR
(400 MHz, D2O): δ = 4.39 (q, J = 10.0 Hz, 1 H, 6-H), 4.04 (t, J =
7.8 Hz, 1 H, 1-H), 3.71 (t, J = 8.5 Hz, 1 H, 2-H), 3.67 (dd, J =
11.7, 3.5 Hz, 1 H, 8-Ha), 3.55-3.44 (m, 3 H, 8-Hb, 9-Ha, 9-Hb),
3.19 (dd, J = 10.0, 5.2 Hz, 1 H, 5-Ha), 3.02–2.95 (m, 2 H, 3-H, 7a-
H), 2.80 (dd, J = 10.0, 5.2 Hz, 1 H, 5-Hb), 2.21 (q, J = 5.9 Hz, 1
H, 7-H) ppm. 13C NMR (50 MHz, D2O): δ = 80.2 (d, C-1), 77.5
(d, C-2), 74.5 (d, C-6), 70.6, 68.5 (d, C-3, C-7), 62.7 (t, C-8), 61.3
(t, C-9), 60.4 (t, C-5), 52.9 (d, C-7a) ppm. MS (EI): m/z (%) = 188
(100), 170 (10), 159 (13), 142 (14), 128 (83), 116 (26), 68 (38), 55
(24). C9H17NO5 (219.23): calcd. C 49.31, H 7.82, N 6.39; found C
49.06, H 7.43, N 6.54.
7-Deoxy-6-O-(α-D-glucopyranosyl)-7-(methoxycarbonyl)-5-oxocasu-
arine (10): Pd (10% on C, 150 mg) was added to a stirred solution
of 22 (125 mg, 0.118 mmol) in MeOH/AcOEt (3:1, 12 mL). The
suspension was stirred at room temp. under hydrogen for 4 d, then
filtered through Celite® and washed with MeOH. Concentration
under reduced pressure afforded pure 10 as a waxy solid (48 mg,
96%). [α]D21 = +75.3 (c = 0.15, MeOH). 1H NMR (400 MHz, D2O):
δ = 5.18 (d, J = 3.6 Hz, 1 H, 1-H), 4.97 (d, J = 9.6 Hz, 1 H, 6-H),
4.08 (dd, J = 6.8, 6.4 Hz, 1 H, 2-H), 3.88 (dd, J = 7.6, 7.2 Hz, 1
H, 1-H), 3.80–3.55 (m, 11 H, 5-H, OCH3, 4-H, 3-H, 6-Ha, 6-Hb,
8-Ha, 7a-H, 3-H), 3.41 (dd, J = 9.6, 3.7 Hz, 1 H, 2-H), 3.37 (t,
J = 9.6 Hz, 1 H, 8-Hb), 3.28 (dd, J = 9.4, 8.2 Hz, 1 H, 7-H) ppm.
13C NMR (50 MHz, D2O): δ = 171.9, 171.5 (s, C=O), 98.8 (d, C-
1), 79.2 (d, C-6), 78.3, 77.3, 72.2, 72.1, 70.9, 68.6, 61.4, 60.9 (d, 1
C), 59.5, 52.2 (t, 1 C), 52.8 (q, OMe), 52.2 (d, 1 C) ppm. IR (KBr):
ν˜ = 3420 (OH), 1710 (C=O), 1684 (C=O), 1205, 1143, 1024 cm–1.
HRMS (ESI): calcd. for C16H25NO12Na [M + Na]+ 446.1269;
found 446.1266. C16H25NO12 (423.37): calcd. C 45.39, H 5.95, N
3.31; found C 44,93, H 6.27, N 3,37.
6-O-α-D-Tris(benzyloxy)-5-oxo-6-O-(2,3,4,6-tetra-O-benzyl-α-D-gluco-
pyranosyl)-7-homocasuarine (23): A 2  solution of LiBH4 in THF
(0.42 mL) was added dropwise to a cooled (0 °C) solution of 22
(221 mg, 0.21 mmol) in dry THF (1.5 mL). The reaction mixture
was stirred at room temp. overnight, and then, after cooling to
0 °C, H2O was added dropwise. The mixture was then filtered
through Celite®, washed with CHCl3 and concentrated under re-
duced pressure. The residue was purified by flash column
chromatography on silica gel (EtOAc/hexane, 1:4) to afford pure
23 (Rf = 0.33, EtOAc/petroleum ether, 1:3) as a colourless oil
(134 mg, 62%). [α]D23 = +44.4 (c = 0.4, CHCl3). 1H NMR
(400 MHz, CDCl3): δ = 7.47–7.08 (m, 35 H, Ar), 5.68 (d, J =
3.6 Hz, 1 H, 1-H), 5.09 (d, J = 11.7 Hz, 1 H, Bn), 5.02 (d, J =
10.9 Hz, 1 H, Bn), 4.81–4.75 (m, 3 H, Bn), 4.72 (d, J = 7.6 Hz, 1
H, 6-H), 4.60–4.40 (m, 9 H, Bn), 4.26 (dd, J = 3.6, 4 Hz, 1 H, 2-
H), 4.21 (m, 1 H, 3-H), 3.94 (t, J = 9.2 Hz, 1 H, 3-H), 3.87–3.66
(m, 6 H, 5-H, 6-Ha, 7a-H, 8-Ha,b, 1-H), 3.60 (dd, J = 9.2,
3.6 Hz, 1 H, 2-H), 3.45 (d, J = 5.2 Hz, 2 H, 9-Ha,b), 3.37 (dd, J
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= 9.8, 7.6 Hz, 1 H, 6-Hb), 3.26 (dd, J = 10.8, 9.2 Hz, 1 H, 4-H),
3.13 (t, 1 H, OH), 2.44 (m, 1 H, 7-H) ppm. 13C NMR (50 MHz,
CDCl3): δ = 171.4 (s, C=O), 138.4–136.7 (s, 7 C, Ar), 128.7–127.3
(d, 35 C, Ar), 94.9 (d, C-1), 87.7 (d, C-1), 86.1 (d, C-2), 81.4 (d,
C-3), 78.2 (d, C-2), 77.4 (d, C-4), 75.6 (d, C-6), 75.6, 74.9, 73.3,
73.0, 71.9, 71.7, 71.2 (t, Bn), 70.5 (d, C-5), 68.8 (t, C-6), 68.7 (t, C-
9), 60.5 (d, C-7a), 58.4 (t, C-8), 58.4 (d, C-3), 50.4 (d, C-7)
ppm. IR (CDCl3): ν˜ = 3463 (OH), 3032, 2925, 2870, 1703 (C=O),
1454, 1078 cm–1. HRMS (ESI): calcd. for C64H67NO11Na [M +
Na]+ 1048.4606; found 1048.4602. C64H67NO11 (1026.22): calcd. C
74.90, H 6.58, N 1.36; found C 74.65, H 6.69, N 1.53.
6-O-(α-D-Glucopyranosyl)-5-oxo-7-homocasuarine (9): Pd (10% on
C, 230 mg) was added to a stirred solution of 23 (134 mg,
0.13 mmol) in MeOH (13 mL). The suspension was stirred at room
temp. under hydrogen for 24 h, then filtered through Celite® and
washed with MeOH. Concentration under reduced pressure af-
forded pure 9 as a waxy solid (37 mg, 72%). [α]D26 = +59.3 (c =
0.75, MeOH). 1H NMR (400 MHz, D2O): δ = 5.18 (d, J = 4 Hz,
1 H, 1-H), 4.57 (d, J = 9.6 Hz, 1 H, 6-H), 4.09 (dd, J = 6.8, 6.4 Hz,
1 H, 2-H), 3.82–3.58 (m, 10 H, 1-H, 3-H, 8-Ha,b, 9-Ha, 3-H,
4-H, 5-H, 6-Ha,b), 3.50–3.45 (m, 2 H, 7a-H, 2-H), 3.34 (dd, J =
9.6, 9.2 Hz, 1 H, 9-Hb), 2.50–2.44 (m, 1 H, 7-H) ppm. 13C NMR
(50 MHz, D2O): δ = 173.9 (s, C=O), 98.6 (d, C-1), 79.9 (d, C-6),
77.9, 77.3, 72.7, 72.5, 71.2, 69.3, 62.1, 61.2 (d, 1 C), 60.3, 59.8, 59.7
(t, 1 C), 50.0 (d, 1 C) ppm. IR (KBr): ν˜ = 3378 (OH), 1689 (C=O)
cm–1. HRMS (ESI): calcd. for C65H67NO12Na [M + Na]+
418.1320; found 418.1312. C15H25NO11 (395.36): calcd. C 45.57, H
6.37, N 3.54; found C 45.25, H 6.28, N 3.04.
6-O-(α-D-Glucopyranosyl)-5-oxocasuarine (3): Pd (10% on C,
180 mg) was added to a stirred solution of 24 (159 mg, 0.144 mmol)
in MeOH/EtOAc (7:1, 12 mL). The suspension was stirred at room
temp. under hydrogen for 24 h, then filtered through Celite® and
washed with MeOH. Concentration under reduced pressure af-
forded pure 3 (42 mg, 0.110 mmol, 77% yield) as a hygroscopic
pale-yellow oil. [α]D24 = +37.6 (c = 0.28, MeOH). 1H NMR
(400 MHz, D2O): δ = 5.14 (d, J = 3.7 Hz, 1 H, 1-H), 4.53 (d, J =
8.4 Hz, 1 H, 6-H), 4.27 (dd, J = 8.4, 7.0 Hz, 1 H, 7-H), 4.08 (t, J
= 6.1 Hz, 1 H, 2-H), 3.90 (t, J = 6.8 Hz, 1 H, 1-H), 3.78–3.58 (m,
7 H, 3-H, 3-H, 5-H, 6-Ha,b, 8-Ha,b), 3.50–3.44 (m, 2 H, 2-H,
7a-H), 3.34 (t, J = 9.5 Hz, 1 H, 4-H) ppm. 13C NMR (50 MHz,
D2O): δ = 170.8 (s, C-5), 98.0 (d, C-1), 81.6 (d, C-6), 78.2 (d, 1
C), 77.3 (d, C-7), 76.9 (d, C-2), 71.9 (d), 71.5 (d), 70.5 (d), 68.6
(d), 64.7 (d), 60.7 (d), 59.6 (t), 58.8 (t) ppm. MS (ESI): m/z (%) =
404 (100) [M + Na]+. C14H23NO11 (381.33): calcd. C 44.10, H 6.08,
N 3.67; found C 43.96, H 6.19, N 3.42.
Enzymatic Assays: The experiments were performed essentially as
follows: 0.01–0.5 unit/mL of enzyme (1 unit = 1 mol of glycoside
hydrolysed/min), preincubated at 20 °C with the inhibitor for
5 min, and increasing concentrations of an aqueous solution of the
appropriate p-nitrophenyl glycoside substrates (buffered at the opti-
mum pH of the enzyme) were incubated at 37 °C for 20 min. The
reactions were stopped by the addition of 0.3  sodium borate
buffer (100 µL, pH = 9.8). The p-nitrophenolate formed was quan-
tified at 405 nm, and IC50 values were calculated. Double-recipro-
cal (Lineweaver–Burk) plots were used to determine the inhibition
characteristics and the Ki values for each compound.
Molecular Modelling: The ligand structures (Table 1) were con-
structed by using Maestro v8.5.[29] All the molecules were subjected
to conformational search and clusterization with Macromodel
9.6[30] in order to sample the most accessible conformations of both
the aglyconic and glucose moieties. The bridgehead nitrogen atoms
were treated as ionized to better simulate the physiological condi-
C. Bonaccini, F. Cardona et al.FULL PAPER
tions, except for the lactam intermediates. All the docking calcula-
tions were performed by using Glide 5.0.[31] The crystal structure
of glucoamylase-471 from Aspergillus awamori complexed with 1-
deoxynojirimycin (PDB ID: 1DOG)[26a] was downloaded from the
PDB and prepared according to the recommended Protein Prepa-
ration module in Maestro 8.5 by using default input parameters
(no scaling factors for the van der Waals radii of non-polar protein
atoms, 0.8 scaling factor for non-polar ligand atoms). This pro-
cedure was used to remove water molecules (except for molecule
Wat501, which is considered as part of the target structure), to
assign missing hydrogen atoms, to optimize hydrogen-bonding in-
teractions and to reduce structural problems. The grids were pre-
pared with the centre of the site defined by the centre of the com-
plexed ligand. All the relevant conformations for the ligands in
Table 1 were docked in the binding site by using the SP scoring
function to score the ligand poses. The docking calculations were
performed in the presence of Wat501. After completion of each
docking run, one pose per ligand conformation was saved. Finally,
for each ligand, the poses (conformations) with the lowest (best)
value of either the model energy score (Emodel)[32] or the Glide
score were chosen.
Supporting Information (see footnote on the first page of this arti-
cle): Syntheses of 5, 8, 8a, 10a, 16a, 19, 19a,b, 22 and 22a, copies
of the NMR spectra of 3–11, 8a, 10a, 16–23, 16a, 19a,b and 22a,
HR-ESI-TOF-MS spectra and the docking results for 2.
Acknowledgments
We thank the Ministero dell’Istruzione, dell’Università e della
Ricerca (PRIN 2007 and 2008) and the Ente Cassa di Risparmio
di Firenze, Italy, for financial support. Ente Cassa di Risparmio di
Firenze, Italy, is also gratefully acknowledged for a grant to C. B.
and for granting a 400 MHz NMR spectrometer. B. Innocenti and
M. Passaponti (Dipartimento di Chimica “Ugo Schiff”) are ac-
knowledged for technical assistance. Consorzio Interuniversitario
Nazionale “Metodologie e Processi Innovativi di Sintesi” is grate-
fully acknowledged for a grant to C. P. We also thank the Swiss
National Science Foundation for financial support and Dr. L.
Menin and Dr. A. Razaname for the HRMS measurements.
[1] a) P. Compain, O. R. Martin (Eds.), Iminosugars: from synthe-
sis to therapeutic applications, Wiley-VCH, Weinheim, 2007; b)
N. Asano, Curr. Top. Med. Chem. 2003, 3, 471–484, and refer-
ences cited therein.
[2] a) N. Asano, Glycobiology 2003, 13, 93R–104R, and references
cited therein; b) N. Asano, R. J. Nash, R. J. Molyneux, G. W. J.
Fleet, Tetrahedron: Asymmetry 2000, 11, 1645–1680; c) I. Rob-
ina, A. J. Moreno-Vargas, A. T. Carmona, Curr. Drug Metab.
2004, 5, 329–361.
[3] a) A. Vasella, T. D. Heightman, Angew. Chem. Int. Ed. 1999,
38, 750–770; b) T. M. Gloster, P. Meloncelli, R. V. Stick, D.
Zechel, A. Vasella, G. J. Davies, J. Am. Chem. Soc. 2007, 129,
2345–2354; c) M. E. C. Caines, S. M. Hancock, C. A. Tarling,
T. M. Wrodnigg, R. V. Stick, A. E. Stütz, A. Vasella, S. J. With-
ers, N. C. J. Strynadka, Angew. Chem. Int. Ed. 2007, 46, 4474–
4476; d) T. M. Gloster, G. J. Davies, Org. Biomol. Chem. 2010,
8, 305–320.
[4] a) A. A. Watson, R. J. Nash, E. L. Evinson, PCT Int. Appl.
WO2004064715, 2004; b) R. J. Nash, A. A. Watson, E. L. Evin-
son, H. St. P. Parry, PCT Int. Appl. WO2005070418, 2005.
[5] a) A. A. Watson, G. W. J. Fleet, N. Asano, R. J. Molyneux,
R. J. Nash, Phytochemistry 2001, 56, 265–295; b) T. Yamashita,
K. Yasuda, H. Kizu, Y. Kameda, A. A. Watson, R. J. Nash,
G. W. J. Fleet, N. Asano, J. Nat. Prod. 2002, 65, 1875–1881; c)
N. Asano, K. Ikeda, M. Kasahara, Y. Arai, H. Kizu, J. Nat.
www.eurjoc.org © 2010 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim Eur. J. Org. Chem. 2010, 5574–55855584
Prod. 2004, 67, 846–850; d) A. Kato, N. Kato, I. Adachi, J.
Hollinshead, G. W. J. Fleet, C. Kuriyama, K. Ikeda, N. Asano,
R. J. Nash, J. Nat. Prod. 2007, 70, 993–997; e) J. P. Saludes,
S. C. Lievens, T. F. Molinski, J. Nat. Prod. 2007, 70, 436–438.
[6] a) H. Paulsen, I. Sangster, K. Heyns, Chem. Ber. 1967, 100,
802–815; b) M. Yagi, T. Kouno, Y. Aoyagi, H. Murai, Nippon
Nogei Kagaku Kaishi 1976, 50, 571–572.
[7] a) I. Pastuszak, R. J. Molyneux, L. F. James, A. D. Elbein, Bio-
chemistry 1990, 29, 1886–1891; b) F. Cardona, A. Goti, A.
Brandi, Eur. J. Org. Chem. 2007, 1551–1565; c) F. Cardona, G.
Moreno, F. Guarna, P. Vogel, C. Schuetz, P. Merino, A. Goti,
J. Org. Chem. 2005, 70, 6552–6555.
[8] B. Macchi, A. Minutolo, S. Grelli, A. Mastino, F. Cardona,
F. M. Cordero, A. Brandi, Glycobiology 2010, 20, 500–506.
[9] a) M. J. Humphries, K. Matsumoto, L. S. White, K. Olden,
Cancer Res. 1986, 46, 5215–5222; b) G. K. Ostrander, N. K.
Scribner, L. R. Rohrschneider, Cancer Res. 1988, 48, 1091–
1094; c) S. P. Sunkara, P. S. Liu, Eur. Pat. Appl. EP 373663,
1990; d) M. A. Spearman, J. M. Ballon, J. M. Gerrard, A. H.
Greenberg, J. A. Wright, Cancer Lett. 1991, 60, 185–191; e)
R. Pili, J. Chang, R. A. Partis, R. A. Mueller, F. J. Chrest, A.
Passaniti, Cancer Res. 1995, 55, 2920–2926; f) C. S. Yee, E. D.
Schwab, J. E. Lehr, M. Quigley, K. J. Pienta, Anticancer Res.
1997, 17, 3659–3663.
[10] a) R. J. Nash, P. I. Thomas, R. D. Waigh, G. W. J. Fleet, M. R.
Wormald, P. M. Q. Lilley, D. J. Watkin, Tetrahedron Lett. 1994,
35, 7849–7852; b) M. R. Wormald, R. J. Nash, A. A. Watson,
B. K. Bhadoria, R. Langford, A. Sims, G. W. J. Fleet, Car-
bohydr. Lett. 1996, 2, 169–174.
[11] F. Cardona, C. Parmeggiani, E. Faggi, C. Bonaccini, P. Grat-
teri, L. Sim, T. M. Gloster, S. Roberts, G. J. Davies, D. R. Rose,
A. Goti, Chem. Eur. J. 2009, 15, 1627–1636.
[12] K. Hiromi, Z. I. Hamauzu, K. Takahashi, S. Ono, J. Biochem.
1966, 59, 411–418.
[13] B. C. Saha, J. G. Zeikus, Starch/Staerke 1989, 41, 57–64.
[14] J. Sauer, B. W. Sigurskjold, U. Christensen, T. P. Frandsen, E.
Mirgrorodskaya, M. Harrison, P. Roepstorff, B. Svensson, Bi-
ochim. Biophys. Acta 2000, 1543, 275–293.
[15] A. Brandi, F. Cardona, S. Cicchi, F. M. Cordero, A. Goti,
Chem. Eur. J. 2009, 15, 7808–7821.
[16] a) F. Cardona, E. Faggi, F. Liguori, M. Cacciarini, A. Goti,
Tetrahedron Lett. 2003, 44, 2315–2318; b) A. T. Carmona,
R. H. Wightman, I. Robina, P. Vogel, Helv. Chim. Acta 2003,
86, 3066–3073; c) S. Desvergnes, S. Py, Y. Vallée, J. Org. Chem.
2005, 70, 1459–1462; d) J. Revuelta, S. Cicchi, A. Goti, A.
Brandi, Synthesis 2007, 485–504; e) E.-L. Tsou, Y.-T. Yeh, P.-
H. Liang, W.-C. Cheng, Tetrahedron 2009, 65, 93–100; f) X.-G.
Hu, Y.-M. Jia, J. Xiang, C.-Y. Yu, Synlett 2010, 982–986.
[17] For other total syntheses of 7-deoxycasuarine, see: a) J.-B.
Behr, A. Erard, G. A. Guillerm, Eur. J. Org. Chem. 2002, 1256–
1262; b) ref.[16b]; c) J.-B. Behr, A. Gainvors-Claisse, A. Belrabe,
Nat. Prod. Res. 2006, 20, 1308–1314.
[18] For other total syntheses of hyacinthacine A2, see: a) L. Ram-
baud, P. Compain, O. R. Martin, Tetrahedron: Asymmetry
2001, 12, 1807–1809; b) I. Izquierdo, M. T. Plaza, F. Franco,
Tetrahedron: Asymmetry 2003, 14, 3933–3935; c) ref. 16c; d) P.
Dewi-Wuelfing, S. Blechert, Eur. J. Org. Chem. 2006, 1852–
1856; e) J. Calveras, J. Casas, T. Parella, J. Joglar, P. Clapes, Adv.
Synth. Catal. 2007, 349, 1661–1666; f) C. Ribes, E. Falomir, M.
Carda, J. A. Marco, Tetrahedron 2009, 65, 6965–6971; g) I.
Delso, T. Tejero, A. Goti, P. Merino, Tetrahedron 2010, 66,
1220–1227.
[19] F. Cardona, A. Goti, C. Parmeggiani, P. Parenti, M. Forcella,
P. Fusi, L. Cipolla, S. M. Roberts, G. J. Davis, T. M. Gloster,
Chem. Commun. 2010, 46, 2629–2631.
[20] S. Nukui, M. Sodeoka, H. Sasai, M. Shibasaki, J. Org. Chem.
1995, 60, 398–404.
[21] For other total syntheses of casuarine, see: a) S. E. Denmark,
A. R. Hurd, Org. Lett. 1999, 1, 1311–1314; b) S. Denmark,
A. R. Hurd, J. Org. Chem. 2000, 65, 2875–2886; c) I. Izquierdo,
Casuarine Analogues
M. T. Plaza, J. A. Tamayo, Tetrahedron 2005, 61, 6527–6533;
d) J. Van Ameijde, G. Horne, M. R. Wormald, R. A. Dwek,
R. J. Nash, P. W. Jones, E. L. Evinson, G. W. J. Fleet, Tetrahe-
dron: Asymmetry 2006, 17, 2702–2712; e) T. Ritthiwigrom,
A. C. Willis, S. G. Pyne, J. Org. Chem. 2010, 75, 815–824.
[22] C. Parmeggiani, D. Martella, F. Cardona, A. Goti, J. Nat.
Prod. 2009, 72, 2058–2060.
[23] A. Brandi, S. Cicchi, F. M. Cordero, R. Frignoli, A. Goti, S.
Picasso, P. Vogel, J. Org. Chem. 1995, 60, 6806–6812.
[24] A. Kato, E. Kano, I. Adachi, R. J. Molyneux, A. A. Watson,
R. J. Nash, G. W. J. Fleet, M. R. Wormald, H. Kizu, K. Ikeda,
N. Asano, Tetrahedron: Asymmetry 2003, 14, 325–331.
[25] N. Asano, H. Kuroi, K. Ikeda, H. Kizu, Y. Kameda, A. Kato,
I. Adachi, A. A. Watson, R. J. Nash, G. W. J. Fleet, Tetrahe-
dron: Asymmetry 2000, 11, 1–8.
[26] a) E. M. S. Harris, A. E. Aleshin, L. M. Firsov, R. B. Hon-
zatko, Biochemistry 1993, 32, 1618–1626; b) A. E. Aleshin, B.
Stoffer, L. M. Firsov, B. Svensson, R. B. Honzatko, Biochemis-
try 1996, 35, 8319–8328; c) A. Aleshin, A. Golubev, L. M. Fir-
sov, R. B. Honzatko, J. Biol. Chem. 1992, 267, 19291–19298; d)
Eur. J. Org. Chem. 2010, 5574–5585 © 2010 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim www.eurjoc.org 5585
A. E. Aleshin, C. Hoffman, L. M. Firsov, R. B. Honzatko, J.
Mol. Biol. 1994, 238, 575–591; e) A. E. Aleshin, L. M. Firsov,
R. B. Honzatko, J. Biol. Chem. 1994, 269, 15631–15639.
[27] A. M. Davis, S. J. Teague, Angew. Chem. Int. Ed. 1999, 38, 736–
749.
[28] T. Weimar, B. Stoffer, B. Svensson, B. M. Pinto, Biochemistry
2000, 39, 300–306.
[29]Maestro, v. 8.5, Schrödinger, L.L.C., New York, 2008, available
at http://www.schrodinger.com.
[30]Macromodel, v. 9.6, Schrödinger, L.L.C., New York, 2008,
available at http://www.schrodinger.com.
[31]Glide, v. 5.0, Schrödinger, L.L.C., New York, 2008, available at
http://www.schrodinger.com.
[32] R. A. Friesner, J. L. Banks, R. B. Murphy, T. A. Halgren, J. J.
Klicic, D. Mainz, M. P. Repasky, E. H. Knoll, M. Shelley, J. K.
Perry, D. E. Shaw, P. Francis, P. S. Shenkin, J. Med. Chem.
2004, 47, 1739–1749.
Received: May 5, 2010
Published Online: August 25, 2010
Ringraziamenti
Ringraziamenti
Gratuitamente avete ricevuto, gratuitamente date (Mt10,8) 
Alla fine di questo percorso di studi il pensiero più grande va alla mia Famiglia, 
alla quale dedico di cuore questo lavoro. E’ grazie ai miei genitori, alla mia
nonna Nella e a Barbara che sono arrivato fino a qui. Grazie ai loro 
incoraggiamenti, ai loro consigli, alla loro pazienza e un po’ … anche grazie agli 
squisiti mangiarini della mia nonna Nella. 
Grazie alla Professoressa Paola Gratteri per aver avuto fiducia in me, per il 
prezioso aiuto e per il sostegno che mi ha sempre dato. Un sentito grazie va poi a 
tutte le persone con cui ho condiviso questi anni di dottorato nel gruppo di 
Molecular Modeling. 
Grazie al Professor Piero Procacci per la sua disponibilità e per avermi 
permesso di svolgere una parte del dottorato in collaborazione con il suo gruppo 
di ricerca. 
Grazie a Simone per l’aiuto che mi ha dato e per la pazienza che ha avuto. 
Un grazie, infine, a tutte quelle persone che ho conosciuto in questi anni di 
dottorato e che mettono tanta passione in quello che fanno. 
Matteo.
